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Angiogenesis is one of the vital events for organ development and differentiation during 
embryogenesis as well as wound healing and reproductive functions in adults. Angiogenesis also 
contributes significantly to tumor growth and metastasis. Hence, search for effective 
antiangiogenesis agents and therapy is an emerging field in the past decades. From the existing 
experience, the mono-antiangiogenesis therapy, however, is hampered by the fact that cancer 
cells could evade the single antiangiogenesis treatment designated to control tumor endothelial 
cell growth and tumor cell survival. Therefore, combinatorial therapy in which antiangiogenetic 
agent and chemotherapeutic drug administrated in a scheduled manner could result in a much 
more favorable therapeutic effect.  
In this thesis, we designed and fabricated several multifunctional and/or combinatorial 
nanoparticulated delivery systems aiming to disrupt tumor endothelial cells and induce apoptosis 
in tumor cells simultaneously for antiangiogenesis and anticancer therapy.  To realize the specific 
tumor site targeting ability, we used a RGD (Arg-Gly-Asp) sequence containing peptide as the 
targeting ligand, which could target not only to the universally available endothelial cells in 
tumor microenvironment, but also to some specific types of malignant cancer cells via the 
overexpressed integrin αvβ3 and/or αvβ5 on cell membrane. In our first study, we investigated the 
potency of our designed doxorubicin conjugated nanoparticle decorated with PEG (poly(ethylene 
glycol)) and RGD peptide on surface for drug delivery and apoptosis induction in three malignant 
cancer cells, DU145, MDA-MB-231, and B16F10. All the three cancer cells were reported to 
express integrin αvβ3 and/or αvβ5 on cell membrane in different extents. Results showed that this 
drug conjugated targeted delivery system could be taken up by malignant cells efficiently; and its 
apoptosis induction ability on particular cancer cells was also effective, even though the overall 
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therapeutic efficacy of the conjugated anticancer drug was, to some extent, compromised after 
conjugation. In addition, the drug release profile of doxorubin from the matrix was in a sustained 
release manner (zero-order, r2 > 0.97). 
In our second study, we prepared a RGD modified core-shell nanocapsule delivery system to 
investigate the capacity of temporal release of antiangiogenetic drug and anticancer drug in vitro. 
We found that the drug release profiles of the encapsulated drugs, paclitaxel (PTX) and 
combretastatin (CA4) could be well-controlled by changing some preparation parameters, such as 
the density of phospholipid or matrix materials fed. We also found that the uptake of this 
nanocapsule by the endothelial cells was efficient, and the endothelial cellular cytoskeleton could 
be effectively disrupted by the antiangiogenetic agent, CA4. The PTX loaded in the nanoparticle 
core still demonstrated effective therapeutic effect to cancer cells.  What is more important, our 
results indicated that the sequential release of CA4 and PTX from the nanocapsule could 
temporally diminish endothelial cells before eliminating the cancer cells with the potential to shut 
down the tumor microvasculature and trap the anticancer drug inside the tumor. Thus, it was 
evidenced that antiangiogenesis and anticancer activities could be successfully realized with 
appropriate formulation design and material choice. 
In our third study, we employed a xenograft tumor bearing mouse model to evaluate our 
nanoparticulate delivery system for combinatorial therapy. PTX and CA4 were co-formulated 
into the RGD decorated nanoparticle in a robust nanoprecipitation method. Results from the in 
vivo model showed that malignant tumor growth was significantly suppressed with this 
combinatorial method, and histological examination revealed that the mechanism underlining this 
encouraging therapeutic efficacy was the disruption of tumor vasculature and tumor apoptosis 
induction by the combined drugs. To establish the hypothesis on the advantage of having 
temporal delivery of antiangiogenesis and anticancer drugs with our nanoparticulate delivery 
system, we further designed a micelle delivery system without RGD peptide decorated on the 
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surface of the nanoparticle , but the size of this delivery system was controlled as small as about 
70nm with uniform size distribution. To maximize the drug loading efficiency, and control the 
drug release manner, we fabricated an amphiphilic polymer (poly(lactic acid)-poly(ethylene 
glycol): PLA-PEG) with carefully adjusted molecular weight, and the polymer was then 
conjugated to the chemotherapeutic agent, PTX via hydrolysable ester bond. The construct was 
then used to formulate into micelles physically loaded with CA4. The micelles were characterized 
with the expected sequential drug release pattern. To test the efficacy of the micelles, three 
animal models were utilized and the findings confirmed that this sequential drug delivery system 
was able to inhibit the angiogenesis progress, suppress primary tumor proliferation and 
angiogenesis, and also prevent the metastasis of malignant tumor. In the first Matrigel Plug assay, 
this sequential delivery system presented significant angiogenesis inhibition effect under the 
growth factor stimulation. In the second tumor bearing mice model, the sequential delivery 
system demonstrated the tumor growth reduction by inducing the tumor cell apoptosis and tumor 
vascular disruption. In the third intrasplenic metastasis model, treatment with this nanoparticle 
with temporal drug release resulted in extended animal survival time and much less, if not at all, 
metastasis spots in animal liver when compared with other controls.  
In conclusion, our results supported the hypothesis that the nanoparticulated combinatorial drug 
delivery system for simultaneous antiangiogenesis and anticancer activities could improve the 
therapeutic outcome. The nanoparticle formulations described in this thesis were all simple, 
robust and easy to be fabricated. This may facilitate the scale-up production of these products for 
clinical testing. The materials chosen for the formulations were all biofriendly and/or 
biodegradable, with minimum potential toxicity. Despite the positive and encouraging results 
with these nanoparticulate delivery systems observed in these studies, many further investigations 
remain to be done in the future, such as the genetic analysis of the therapeutic efficacy or 
alternative combination cocktail for other drugs or diseases.  
X 
 
LIST OF PUBLICATIONS 
 
1. Wang Z., Chui WK., Ho PC. Design of a Multifunctional PLGA Nanoparticulate Drug 
Delivery System: Evaluation of its Physicochemical Properties and Anticancer Activity to 
Malignant Cancer Cells. Pharmaceutical Research.  2009; 26 (5) 1162-1171. 
2. Wang JZ., Loh KP., Wang Z., Yang YL., Zhong YL., Xu QH., Ho PC. Fluorescent Nanogel 
of Arsenic Sulfide Nanoclusters. Angew. Chem. Int. Ed. 2009; 48 (34) 6282-6285.    
3. Wang JZ., Lin M., Yan YL., Wang Z., Ho PC., Loh KP. CdSe/AsS Core-Shell Quantum 
Dots: Preparation and Two-Photon Fluorescence. J. Am. Chem. Soc. 2009; 131(32), 11300-
11301.      
4. Wang Z., Chui WK., Ho PC. Integrin targeted drug and gene delivery. Expert opinion on 
drug delivery. 2010; 7(2), 159-171. 
5. Wang Z., Chui WK. Ho PC. Nanoparticulate delivery system targeted to tumor 
neovasculature for combined anticancer and antiangiogenesis therapy. Pharmaceutical 
Research. (In Press) 
6. Wang Z., Ho PC. A nanocapsular combinatorial sequential drug delivery system for               
antiangiogenesis and anticancer activities. Biomaterials. 2010; 31(27), 7115-7123. 
7. Wang Z., Ho PC. Core-shell nanocapsule targeting to the tumor vasculature with sequential 
drug delivery for antivasculature and anticancer activities. Small. 2010; 6(22), 2576-2583. 
8. Wang Z., Lee T.Y., Ho PC. cRGD-dextran-oleate conjugate self-assembled poly(lactic-co-
glycolic acid) (PLGA) nanoparticle for targeted chemotherapeutic delivery of paclitaxel. 
(Submitted for review). 
9. Wang Z., Liew G. F., Ho PC. Double targeting cRGD-HA-DSPE self-assembled PLGA 




List of Tables 
Table 
1-1  List of the integrin subunit combinations, their distribution, and RGD recognition.           13 
1-2  Selected antiangiogenesis inhibitors in clinical trials.                                                          17 
2-1  Physical characteristics of PLGA based nanoparticles.                                                        34 




List of Figures 
Figure 
1-1  Metastasis from malignant primary tumor to distant site.                                                       4 
1-2  Angiogenesis steps in tumor microenvironment.                                                                    8 
1-3  Doxorubicin-peptide conjugate with formaldehyde space linker.                                         18 
2-1  Scheme of conjugating doxorubicin to PLGA.                                                                      32 
2-2  Schematic route of preparation of Doxo-PLGA-PEG-cRGD nanoparticles.                         33     
2-3  TEM images of PLGA-Doxo nanoparticles.                                                                          35 
2-4  Cytotoxicity results of Doxo-PLGA-PEG-cRGD nanoparticles or doxorubicin to (a) B16F10   
cells, (b) DU145 cells, and (c) MDA-MB-231 cells.                                                              36 
2-5  CLSM results of cellular uptake of Doxo-PLGA-PEG-cRGD nanoparticle in 0.5, 2 and 4 
hours incubation of (a-c) B16F10 cells, (d-f) DU145 cells, (g-i) MDA-MB-231 cells, and (j-l) 
MCF-7 cells.                                                                                                                            38 
2-6  In vitro drug release profile of Doxo-PLGA-PEG-cRGD nanoparticles over 12 days at 37oC, 
100 rpm in shaking water bath.                                                                                                39 
2-7  DNA fragment results from agrose gel electrophoresis.                                                         40 
2-8  Western Blot results: NPs: Doxo-PLGA-PEG-cRGD nanoparticles.                                     40 
3-1  Dynamic light scattering results of PLGA core and nanocapsule (a) and the particle size 
distribution of vasculature targeted nanocapsule (b).                                                               52 
3-2  Scanning transmission electron microscopy (sTEM) image of vasculature targeted 
nanocapsule (a) and CLSM images of 6-coumarin fluorescence (b), nile red fluorescence (c), 
and their overlay image (d).                                                                                                      53    
3-3  MCF-7 cellular viability assay induced by PTX containing PLGA core at different 
concentrations of equivalent PTX.                                                                                           54 
XIII 
 
3-4  Immunofluorescence staining of β-tubulin of HUVEC after treated by blank lipid 
formulation as control (a) and 2.5 μM CA4 equivalent lipid formulation (b) in 24 h 
incubation.                                                                                                                               55 
3-5  Cellular uptake of RGD targeted nanocapsules at 20 min (a) and 6 h incubation (b), 
respectively.                                                                                                                             55 
3-6  Time-dependent HUVEC uptake of RGD surface modified nanocapsule (a-d) and 
nanocapsule without RGD surface modification (e-h).                                                           56 
3-7  Competition assay of HUVEC uptake of RGD surface modified nanocapsule without (a) and 
with (b) free RGD (50 μM) prior addition.                                                                             57 
3-8  In vitro cumulative drug release profiles of nanocapsule for sustained release of 
combretastatin A4 and paclitaxel.                                                                                            58 
3-9  Co-culture assay of endothelial and tumor cells with different treatment methods.               60 
4-1  RGDfK peptide surface modified poly(lactic-co-glycolic acid) (PLGA) nanoparticles 
encapsulated with paclitaxel and combretastatin A4.                                                               71 
4-2  Cellular uptake of targeted nanoparticle and cytoplasm distribution.                                     73 
4-3  Competition assay of cellular uptake of the targeted nanoparticles.                                       74 
4-4  Mechanism study of cellular uptake of nanoparticle.                                                              75 
4-5  Western blot results indicated the potency of T-PTX NPs to induce caspase 3/7 apoptosis 
pathway in B16F10 cancer cells at different drug concentration upon 24 h incubation.         76 
4-6  Immunofluorescent staining of HUVEC illustrates β-tubulin disruption by combretastatin A4 
(CA4) formulation.                                                                                                                   77 
4-7  Changes in tumor growth as a function of time in C57BL6 mice after intravenous treatment 
with PTX and CA4.                                                                                                                  78 
4-8  Histology of tumor tissues with treatment of different formulations.                                     79 
4-9  Change of body weight during treatments.                                                                              80 
XIV 
 
5-1  Synthesis and physicochemical characterization of the nanocapsule.                                   94 
5-2  HUVEC uptake of nanocapsule.                                                                                            96 
5-3  FACS analysis of Annexin V/propidium iodide apoptosis induced by sustained released PTX 
conjugate in nanocapsule.                                                                                                       98 
5-4  CA4 loaded nanocapsule in HUVEC migration inhibition and tube formation disruption 
ability.                                                                                                                                      99 
5-5  Biodistribution study of nanocapsule.                                                                                   100 
5-6  H&E staining of mouse tissues dissected from mice intravenously injected with 10mg/ml 
(nanocapsule concentration) nanocapsule for toxicity evaluation.                                         102 
5-7  Vascular disruption of different formulated nanocapsules in the mouse Matrigel plug assay 
model.                                                                                                                                     102 
5-8  The therapeutic effect of nanocapsule to inhibit primary tumor proliferation and angiogenesis 
without toxicity.                                                                                                                      103 
5-9  Histology of tumor tissues with treatment of different formulations.                                   105 
5-10VEGF expression level with different formulated nanocapsule treatment.                           106 
5-11Therapeutic and preventive effects of different formulated nanocapsules on liver metastasis  




 List of Abbreviations 
XVI 
 
VEGF vascular endothelial growth factor 
VEGFR vascular endothelial growth factor receptor 
SDF-1 stromal derived factor-1 
CXCR4 chemokine receptor 4 
PDGF platelet derived growth factor 
IFN interferon 
ECM extracellular matrix 
VCAM vascular cell adhesion molecule 
MAdCAM mucosal addressin cell adhesion molecule 
tTG tissue-type transglutaminase 
ICAM intercellular cell adhesion molecule 
FGF2 fibroblast growth factor 2 
ADAM a disintegrin-like and metalloproteinase 
MMP matrix metalloproteinases 
MTX methotrexate 
TNFα tumor necrosis factor α 
tTF truncated tissue factor 
EPR enhanced penetration and retention 
PEG poly(ethylene glycol) 
CA4 combretastatin A-4 
PTX paclitaxel 
Doxo doxorubicin 
HGC 5β-cholanic acid 
CN contortrostatin 
PLGA Poly(lactic-co-glycolic acid) 
CLSM confocal laser scanning microscope 
PEMA Poly(ethylene-maleic anhydride) 
NHS N-hydroxysuccinimide 
EDC N-(3-Dimethylaminopropyl)-N′-            
ethylcarbodiimide hydrochloride 
pNC 4-nitrophenyl chloroformate 
TEA triethylamine 
DMF N,N-Dimethylformamide 
MTT 3-(4,5-dimethylthiaol-2-yl)-2,5-   
diphenyltetrazolium bromide 
DMEM Dulbecco's Modified Eagle's Medium 
MES 2-(N-morpholino)ethanesulfonic acid 
TEM transmission electron microscopy 
DAPI 4',6-diamidino-2-phenylindole 
PVA poly(vinyl alcohol) 
E.E. encapsulation efficiency 
E.C. encapsulation capacity 
M.W. molecular weight 
HPMA poly(N-(2-hydroxy-propyl)methacrylamide) 
DSPC distearoyl-sn-glycero-phosphocholine 
HUVEC human umbilical vascular endothelial cells 
FITC fluorescein isothiocyanate 






SAPK2 stress-activated protein kinase 2 
mPEG-PLA Methoxyl poly(ethylene glycol)-poly(lactic  
acid) 
cNC combinatorial nanocapsule 
sTEM scanning transmission electron microscopy 
SEM scanning electron microscopy 
 







Cancer, medically termed as malignant neoplasm, is a class of serious diseases that the 
proliferating mammalian cells present unlimited abnormal growth behaviors, invasion to adjacent 
tissues by intrusion and destruction of surrounding matrix, migration from the original location to 
other near end sites and finally metastasis through blood and lymph node vessels to distant organs.  
It has been reported that cancer has become the leading cause of death worldwide, and it accounts 
for 7.4 million deaths (around 13% of all death cases) in 2004 (1). Deaths from cancer are 
projected to continue rising, and estimated to reach 12 million deaths in 2030 
(http://www.who.int/mediacentre/factsheets/fs297/en/).   
 
Cancer is normally caused by the genetic mutation in transformed cells. It has been evidenced 
that tumorigenesis in human body is a multistep process and that these steps reflect genetic 
alterations which drive the progressive transformation of normal human cells into highly 
malignant derivatives. Many types of cancers are diagnosed in the human population with an age-
dependent incidence implicating four to seven rate-limiting, stochastic events (2). A large number 
of pathological analyses of tissues reveal that lesions appear to present the intermediate steps in a 
process through which cells evolve progressively from normalcy in a series of pre-malignant 
states into invasive cancers (3).   
 
1.1.2 Metastasis of cancer 
Metastasis, the spread of cancer from its primary site to a distant organ, is responsible for the 
major cause of morbidity and mortality of cancer suffering patients rather than the primary 
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tumors. Five-year survival rates for breast cancer drop from nearly 100% when the cancer is 
localized to less than 25% when the cancer has colonized distant sites (4). When cancer is 
detected at an early stage, prior to its wide spreading, surgery excision or irradiation with the 
primary tumor, followed by chemo- or immune- therapies could have successful treatment effects 
to patients. However, when cancer is detected to be in metastatic stages, such treatments are much 
less effective. Furthermore, those patients in whom there is no evidence of metastasis at the time 
of their initial diagnosis, metastases could still be detected in a later time along with the cancer 
recurrence. The breast cancer, for example, is likely to occur metastatic growth even years after 
the patient has been declared cancer free (5). And nearly one-third of breast cancer patients would 
have positive for metastatic disease at the time of initial diagnosis (6). This suggests that a sub-
population of tumor cells had undergone therapy resistance, and disseminated, survived at 
secondary distant sites to recommence uncontrolled growth. The transformation from a non-
malignant to a malignant metastatic phenotype is an evolutionary process in which tumor cells 
progressively acquire aggressive characteristics that result from, or are a consequence of, 
selection of a sub-population of cells that are eventually capable of completing all the metastatic 
cascade steps (7).  
 
Typically, the process of metastasis has been viewed as a series of sequential and interrelated 
biological steps. These steps include dissociation of malignant cells in the primary tumor, local 
invasion, angiogenesis, intravasation of invading cells into the vasculature or lymphatic systems, 
survival in these channels, extravasation, and proliferation at a distant site (Figure 1-1). The 
formation of primary tumor lesion is a dominant requirement for metastasis, and it is estimated 
that approximately 1×106 cells escape into circulation per gram of primary tumor daily (8). Only 
a fraction of cells leaving the primary tumor survive in circulation and even fewer cells colonize 
at the secondary sites (9). As a primary tumor grows, it needs to develop a blood supply that can 
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support its high proliferation with sufficient amount of oxygen and nutrient, and metabolic needs 
— a process termed angiogenesis. Meanwhile, these new blood vessels also provide an escape 
channel by which cells can leave the tumor and enter into the circulation system (10). Besides, 
tumor cells could also enter the circulation system indirectly via the lymphatic system. The action 
that tumor cells escape from the primary site to circulation system via either blood vessels or 
lymphatic vessels is usually called intravasation. While circulating in the blood system, tumor 
cells need to survive until they can arrest in a new organ by extravasating from the circulation 
into the surrounding tissue. The arrival of the tumor cells at the secondary site implies that the 
tumor cells have completed all antecedent steps in the metastatic cascade.  
 
 
Figure 1-1 Metastasis from malignant primary tumor to distant site (Adapted from Nature 
Reviews Cancer vol7, 737-749). 
 
Upon disseminated, tumor cells are believed to be regulated by their immediate 
microenvironment, whereas there is emerging evidence that pre-conditioning of arresting sites 
may occur before tumor cells reach the secondary site. It has been evidenced that melanoma cells 
released soluble factors that stimulated lung fibroblasts to secrete fibronectin creating an 
attachment site for the arrival of α4β1/α4β7 integrins, vascular endothelial growth factor receptor 
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(VEGFR) positive progenitor hematopoietic progenitor cells. These progenitor cells then secreted 
metalloproteinases which released from the matrix, including stromal derived factor-1 (SDF-1) 
that attracted chemokine receptor 4 (CXCR4) positive tumor cells (11).  
 
Formation of a tumor mass at the secondary site is believed to follow some of the same steps as in 
primary tumor growth. The term ‘colonization’ is used herein to implicit the combined influences 
of tumor cell proliferation, apoptosis, dormancy and angiogenesis in the formation of a 
progressively growing lesion in a distant organ. However, the major distinction is that these 
disseminated cells grow in an ectopic environment. Hence, only those cancer cells- ‘seed’ that are 
able to adapt to the new environment – ‘soil’; or those that already possess the ability to respond 
to microenvironmental signals at the ‘foreign’ site; or those cells that can modify the new 
microenvironment can be expected to thrive. In 1889, Stephen Paget reported the ‘seed-soil’ 
model to illustrate the tumor metastasis processes (12). Paget hypothesized that their interaction 
determines metastatic outcome: “When a plant goes to seed, its seeds are carried in all directions; 
but they can only live and grow if they fall on congenial soil.” This observation predicted that the 
tissue environment, composed of a myriad of specialized cell types, extracellular matrices and 
cells recruited to the site, may facilitate tumor metastasis and contribute to the organ selectivity 
sometimes seen in metastatic colonization. However, this idea was challenged in the 1920s by 
James Ewing, who suggested that circulatory patterns between a primary tumor and specific 
secondary organs were sufficient to account for organ-specific metastasis (13). In a later 
experiment, Hart and Fidler confirmed Paget’s hypothesis of non-random tumor cell growth by 
implanting kidney, lung, and ovary tissue fragments in the thighs of mice and showed that B16 
melanoma cells injected intravenously grew only in implanted lung or ovarian tissue (14). These 
preliminary but pioneering experiments demonstrated that disseminated cells arrested in the 
implants at essentially similar numbers but still showed organ selectivity for growth. Therefore, 
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the role of vasculature in organ-selective tumor seeding and growth, although important, may be 
only secondary to the properties of the secondary site and the tumor cell itself. 
 
In fact, these two theories are not mutually exclusive, and current evidence supports a role for 
both factors. In a series of autopsy studies, Leonard Weiss documented that larger numbers of 
bone metastases than would be expected based solely on blood-flow patterns were identified for 
both breast and prostate cancer, for example. In contrast, fewer numbers of skin metastases than 
expected based on blood-flow patterns were found for osteosarcomas, stomach and testicular 
cancers (15, 16). Out of the 16 primary tumor types and 8 target organs that were analyzed, 
metastasis in 66% of the tumor-type-organ pairs seemed to be adequately explained on the basis 
of blood flow alone, whereas the remainders were not. For these remaining tumors, negative 
interactions- that is, fewer metastases than expected based on blood flow between the primary 
and secondary sites - between cancer cells and the environment of the metastatic site were found 
in 14% of cases, and positive interactions were found in 20% of cases (17).  
 
To associate a molecular event with metastasis, its occurrence in primary tumors or disseminated 
cells is correlated with survival or other indicators such as disease-free survival or the presence of 
regional lymph node metastases. Most mechanistic insights into metastasis are derived from 
xenograft studies in rodents (18). Typically, a tumor cell line known to metastasize in vivo is 
manipulated to change the expression or mutation status of a single gene. In spontaneous assays, 
the tumor cells are injected into a site, a primary tumor forms and metastases develop. It is 
preferable to inject cells into an orthotropic location, the tissue of origin. This assay measures the 
complete metastatic process but suffers from poor quantification and slow completion. In 
experimental metastasis assays, tumor cells are injected into the bloodstream from the tail vein or 
other sites. Metastases form more quickly than in spontaneous assays and in greater numbers, 
facilitating statistical analysis. However, a drawback of experimental metastasis assays is that 
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only part of the metastatic process, the post intravasation stage, is modeled. To overcome the 
inherent shortage, several transgenic mouse strains are developed to have both primary tumors 
and spontaneous metastases, and are crossed to other genetically engineered mice to determine 
effects on metastasis. In preclinical studies, a compound is administered to animals either just 
after injection of the tumor cells or after metastases has formed, constituting prevention and 
treatment studies, respectively. Veterinary animals including dogs are increasingly used to test 
therapeutics in the metastatic setting, and for a subset of cancers, their pathophysiology may more 
closely resemble to that of humans (19).  
 
1.1.3 Angiogenesis of cancer 
Angiogenesis, the formation of new blood vessels from the pre-existing capillaries, is one of the 
vital events for organ development and differentiation during embryogenesis  as well as wound 
healing and reproductive functions in the adult (20). During embryonic development, new 
endothelial cells differentiate from stem cells, through a process called vasculogenesis. Although 
different in many respects, vasculogenesis shows some similarities to angiogenesis. However, 
vasculogenesis does not seem to contribute to repair and disease in postembryonic life. In 
angiogenesis, new blood vessels primarily emerge from pre-existing ones although a subset of 
CD34(+)CD133(+) cells expressing VEGFR-3 act as stem cells for postnatal angiogenesis (21). 
In adult life, physiologic stimuli during wound healing and the reproductive cycle in women lead 
to angiogenesis, whereas vasculogenesis is absent (22).  
 
However, angiogenesis also underlines some pathophysiologic conditions, such as cancer, 
rheumatoid arthritis, diabetes mellitus, and coronary artery disease, etc. (23). Typically in cancer 
development, tumor stimulates angiogenesis by directly secreting angiogenetic substances or by 
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activating and releasing angiogenetic compounds stored in the extracellular matrix (24). Tumor 
associated vasculogenesis can also be enhanced by angiogenetic substances secreted by tumor 
lymphocytes, macrophages, and/or mast cells (25, 26). This leads to the activation of nearby 
endothelial cells, which respond by expressing a cell autonomous pattern of behavior that 




Figure 1-2 Angiogenesis steps in tumor microenvironment. Release of angiogenetic substances by 
tumor cells results in the tumor endothelial cell activation and formation of new blood vessels 
(Adapted from The Journal of Urology, vol. 158, 1663-1674).  
 
Once activated, endothelial cells first lead to proteolytic disintegration of basement membrane in 
order to create a blood supply to growing tissues, through a process that is facilitated by proteases. 
Next, chemoattractants and mitogens are activated in order to induce migration of cells into the 
extracellular matrix and their proliferation. Finally, vessel formation is completed by 
differentiation and/or apoptosis of endothelial cells, recruitment of accessory cells, and deposition 
of extracellular matrix (27, 28). Then, endothelial cells acquire organ specific properties, such as 
cell surface markers and/or morphological characteristics according to their environment and 
interactions with adjacent cells (29). Each step is essential to the formation of tumor associated 
neovasculature and represents a potential site of therapeutic manipulation. 
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Tumor associated angiogenesis often develops in a hazard and poorly regulated manner. The 
resultant vessels tend to form right-angle turns and corkscrew spirals, and fail to diminish 
progressively (30). Tumor associated vessels are also more prone to leakage, which contributes to 
edema and leads to enhanced tumor diagnosis (31). The classical neovascular pattern of renal cell 
carcinoma as visualized by angiography reflects the qualitative differences between normal 
vessels and tumor associated vasculature as well as quantitative differences in vessel density. 
Increased vessel density and permeability can also signal neoplasia by creating a visible 
erythematous blush that can be seen on external surfaces of the body (32). 
 
1.1.4 Relationship of angiogenesis with tumor growth and metastasis 
In the past three decades, it has been evidenced that solid tumors must induce angiogenesis to 
grow and metastasize. Tumors smaller than 2 to 3 mm in diameter can obtain adequate nutrient 
support  by diffusion from the existing vasculature but further expansion requires the induction 
and growth of new capillaries (33). Experimental tumors, for example, can hardly grow when 
implanted into nonvascular areas, such the interior chamber of the eye. Nevertheless, when placed 
against the iris, where angiogenesis can occur, they can grow aggressively to cover the entire eye 
(34). Xenograft tumor bearing mice provide additional evidence that tumors are angiogenesis 
dependent. Tumor growth rate is decreased dramatically when the mice are treated with agents 
that specifically inhibit angiogenesis, even though these agents have no direct effect on the tumor 
cells themselves (35, 36). In contrary, tumor growth could be stimulated by treatment with pro-
angiogenesis factors. 
 
Angiogenesis is also critical in tumor metastasis.  Tumor cells can hardly extravasate into the 
circulation system significantly until angiogenesis has been induced, and the augment in tumor 
associated neovasculature also increases the surface area available for intravasation (37). In 
9 
 
addition, metastatic cells seeding at new organs must attract new vessels before they can grow to 
a clinically significant size. Experimental studies have clearly demonstrated that systemic 
administration of antiangiogenic agents can maintain previously established micrometastases in a 
dormant state for prolonged periods (38). Rapid growth of the metastatic deposits ensues when 
the source of the inhibitor is removed. Thus, much of the morbidity associated with malignancy is 
directly or indirectly dependent on the induction of angiogenesis. Weidner et al found 
microvessel density to be an independent predictor of lymph node involvement and distant 
metastasis for women with invasive breast cancer, and proposed that microvessel density could be 
useful for selecting patients who might benefit from aggressive adjuvant therapy (39). The strong 
relationship between degree of angiogenesis and advanced pathological findings in these studies 
reflects the important role of angiogenesis in tumor biology and the metastatic process (32). 
 
1.2 Antiangiogenesis therapy 
 
1.2.1 Antiangiogenesis inhibitors 
As early as 1971, Folkman first hypothesized that tumor growth is angiogenesis dependent, and 
the inhibition of tumor neovasculature could suppress tumor growth and/or metastasis (40). 
Nowadays, numerous strategies for modulation of angiogenesis have been reported. Since 
angiogenesis mainly depends on proper activation, proliferation, adhesion, migration, and 
maturation of tumor endothelial cells. Most approaches to modulate angiogenesis are therefore 
focused on these endothelial functions during angiogenesis process.  
 
Intervention of tumor endothelial cell growth: One of the successful methods for angiogenesis 
inhibition lies in the use of agents that specifically inhibit the tumor endothelial growth. One of 
the first compounds identified to show inhibitory effects on endothelial cell growth is TNP-470, 
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an analog of the fungus-derived antibiotic fumagillin (41). The action mechanism of this 
compound was found to prevent  endothelial cells from entering G1 phase of the cell cycle, 
resulting in a decrease in proliferation (42). In a later time, many endogenous molecules with 
angiostatic activity were discovered, such as thrombospondin-1(43), interferon-inducible protein-
10 (44), etc. Amongst the endogenous antiangiogenesis inhibitors, both endostatin and angiostatin 
have been widely studied and different phases of clinical trials are undergoing. Angiostatin is an 
internal fragment of plasminogen with multiple antiangiogenic activities in vitro and in vivo (45). 
Endostatin is a proteolytic fragment of collagen XVIII that affects endothelial cell survival via the 
induction of an imbalance between the antiapoptotic proteins Bcl-2 and Bcl-XL and the 
proapoptotic protein Bax (46).  
 
Another widely accepted method for antiangiogenesis therapy is the interference of angiogenetic 
growth factor such as VEGF, PDGF or their receptors. Typically, VEGF plays a vital role in the 
tumor development and angiogenesis. Hence, the blockage of VEGF function could effectively 
inhibit the angiogenesis and subsequent tumor growth and metastasis (35). This can be performed 
by treatment with humanized blocking antibodies to these factors, antibodies to their receptors, 
with soluble receptors functioning as antagonists, dominant negative growth factor variants, or 
VEGF antisense constructs. Bevacizumab (Avastin®, Genentech/Roche) has emerged as a 
humanized antibody for angiogenesis inhibition (47). It has high affinity for all isoforms of 
VEGF and causes no immune response in humans. In animal experiments, the parent murine anti-
VEGF antibody has been shown to inhibit tumor growth and metastasis in several tumor models, 
including breast, colon and renal tumors. The antiangiogenic activity of Bevacizumab is 
demonstrated by a reduced tumor vascularity and increased blood vessel perfusion upon treatment 
(48).  In addition, functional interference with growth factor receptor signaling can also be 
performed by specific inhibitors, such as SU5416 (Semaxanib), a specific inhibitor of VEGFR-2 
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phosphorylation (49), or SU11248 (Sutent® , Pfizer), a multi receptor tyrosine kinase inhibitor of 
VEGF receptor cellular signaling (50), etc.   
 
Intervention with endothelial cell adhesion and migration: Because interaction between 
endothelial cell and extracellular matrix is highly involved in the angiogenesis progress for 
endothelial cell adhesion and migration, many efforts have been paid on this step for 
antiangiogenesis purpose. Interferon (IFN), the first identified endogenous angiogenesis inhibitor, 
regulates the angiogenesis by inhibiting the tumor-induced motility of capillary endothelial cells 
as well as the spontaneous migration of other cell types (51). Subsequently, both interferons α and 
β were shown to have in vivo antiangiogenic activities (52). Although interferons are not 
sufficiently active for treatment of all tumors, benign tumors predominantly comprised of 
endothelial cells were reported to be sensitive to treatment with interferon (53).  
 
Another important molecular family which is involved in angiogenesis progress through 
endothelial cell interaction with extracellular matrix is the integrin family.  Integrins are cellular 
surface glycoprotein receptors consisting of a heterodimer of α and β subunits which are 
mutually noncovalently associated. In mammals, integrins have extensive distributions 
throughout the whole body (Table 1-1), and there are 18 α and 8 β subunits assembling 24 
functionally different heterodimers (54). Upon ligand binding, integrins cluster into focal 
contracts containing many different actin-associated proteins, such as α-actin, vinculin, tensin, 
and paxillin, which link the integrin to the cytoskeleton (55). The binding-association can initiate 
intracellular signaling events, and also activate kinase that phosphorylate cytoskeletal proteins 
(56). In turn, the reassembly of actin filaments into stress fibers stimulate integrin clustering, and 
enhance the affinity with ECM proteins (57). Up to now, many types of integrin antagonists have 
been discovered or designed, such as LM609, a mouse anti-human monoclonal antibody raised 
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against αvβ3 integrin (58), or another humanized monoclonal antibody, CNTO 95, which has 
high affinity to αvβ3 and αvβ5 integrins (59). The Arg-Gly-Asp (RGD) mimic peptides are the 
well-investigated integrin antagonists. Cilengitide (EMD 121974, Merck KGaA) (60), ATN-161 
(61), and Integrilin® (62), etc are some of the promising peptide integrin antagonists for effective 
antiangiogenesis activities.  
 
Table 1-1. List of the integrin subunit combinations, their distribution, and RGD recognition 
Integrin  
subunit 
Integrin distribution sites 
RGD 
recognition +/- 
α1β1 laminins, collagens  - 
α2β1 laminins, collagens, chodroadherin - 
α3β1 laminins, fibronectin, thrombospondin, collagen, epiligrin, entactin + 
α4β1 VCAM, fibronectin - 
α4β7 VCAM, MAdCAM, fibronectin NA 
α5β1 fibronectin, fibrinogen + 
α6β1 merosin, kalinin, laminins  - 
α6β4 laminins NA 
α7β1 laminins - 
α8β1 fibronectin, vitronectin, osteopontin, nephronectin, tenascin-C - 
α9β1 tenascin, angiostatin, tenascin-C, osteopontin, VCAM-1, tTG  - 
α10β1 collagens NA 
α11βΙΙΙa fibronectin, fibrogen, fibroblast, von Willebrand factor, vitronectin + 
αDβ2 VCAM, ICAM NA 
αΕβ7 E-cadherin NA 
αLβ2 ICAM-1,2,3 NA 
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αMβ2 fibrinogen, ICAMs, denatured ovalbumin - 
αXβ2 fibrinogen - 
αIIbβ3 
 










β1 vitronectin, fibronectin NA 
β3 
 
Fibronectin, vitronectin, fibrinogen, von Willebrand factor, 
thrombospondin, FGF2, metalloproteinase MMP-2 , ADAM proteins 
+ 
β5 vitronectin + 
β6 tenascin, fibronectin + 
β7 fibronectin, collagens, laminins NA 
β8 vitronectin, fibronectin NA 
βN fibronectin, collagens NA 
Abbreviations: VCAM: vascular cell adhesion molecule; MAdCAM: mucosal addressin cell 
adhesion molecule; tTG: tissue-type transglutaminase; ICAM: intercellular cell adhesion 
molecule; FGF2: fibroblast growth factor 2; ADAM: a disintegrin-like and metalloproteinase. NA: 
data not available. 
 
Intervention with metalloproteinase: Another mechanism of angiogenesis inhibition by inhibiting 
endothelial cell adhesion and migration lies in the specific inhibitors of proteinases that 
proteolyzing the tissue connections, thereby facilitating the endothelial extravasion, migration and 
subsequent vascular formation (63).  Matrix metalloproteinases (MMP) are a homologous family 
of enzymes that are involved in tissue remodeling and morphogenesis. These enzymes are 
capable of degrading all components of the extracellular matrix (64). Increased activity of these 
enzymes has been observed in tumor formation, and therefore inhibitors of MMPs represent an 
attractive approach to treat cancer. Batimastat, marimastat, and prinomastat are all potent broad-
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spectrum MMPs inhibitors, and can prevent or reduce growth, angiogenesis and metastasis of 
several different malignant tumors in numerous animal models (65). Interestingly, it was found 
that a naturally occurring MMP-2 breakdown product, PEX, can inhibit cell-associated 
collagenolytic activity. It is suggested that this breakdown product is an important regulator of 
protease activity during angiogenesis and vasculogenesis (63). A recombinant form of PEX was 
useful in blocking angiogenesis and tumor growth in vivo, providing a novel therapeutic approach 
for angiogenesis inhibition (66).  
 
The vital role of angiogenesis in tumor progression and metastasis has urged researchers to 
investigate more effective angiogenesis inhibitors for better clinical treatment of increasing 
cancer occurrence. Table 1-2 lists some of antiangiogenesis inhibitors in different phases of 
clinical trials.  
 
1.3 Drug delivery system for vascular targeted antiangiogenesis or antitumor therapy  
1.3.1 Conjugation of drug with ligand for vascular targeting 
Integrins are important extracellular molecules that regulate angiogenesis process. They are 
transmembrane glycoproteins, and can be internalized by cells upon activation with anchoring 
ligands, these characteristics can be used to facilitate delivery of medicines into cancerous cells 
and leukocytes. In addition, integrins are overexpressed on angiogenetic endothelial cells and 
neovascular cells, whilst are absent in preexisting endothelial cells and normal organs. And some 
tumor cells also express integrins on their cellular membrane surface. All of these characteristics 
make integrin a good targeting ligand for both tumor and antiangiogenesis targeting therapy. In 
recent years, Jain and co-workers have proposed that certain antiangiogenetic agents can 
transiently normalize the abnormal structure and function of the tumor vasculature, and make it 
more efficient for oxygen, nutrients and drug delivery (67). Thus, combination of vascular 
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targeting antagonists with conventional chemotherapeutical agents can facilitate the penetration 
of drug into tumor, as well as diminish the notorious side effect arising from cytotoxic drugs. 
Generally, there are two classes of molecules that could be conjugated with integrin antagonists: 
1. chemotherapeutical small molecules; 2. biomacromolecules. 
 
It is well-known that the conventional chemotherapeutical drugs are effective in their anti-cancer 
activity. However, their high toxicity to healthy cells limits their clinical efficacy. Thus, 
vectorization of the cytotoxic drugs only to the targeted cancer cells is believed to be a feasible 
approach to circumvent the side-effect to some degree. For instance, Arap et al. coupled the 
tumor vascular homing peptides (both targeting to integrin αv), GDCFC (RGD4C) and 
CNGRCVSGCAGRC (NGR) to doxorubicin, a widely used anticancer drug for a variety of 
cancer treatment (68). The result showed that the integrin targeting peptide - doxorubicin 
conjugate resulted in inhibition of tumor growth, and fewer pulmonary metastases in mice than 
free doxorubicin. In addition, the conjugated doxorubicin was found to be less toxic to liver and 
heart than the free drug. In a similar manner, Kim and co-workers also showed that RGD4C 
conjugated doxorubicin was also able to inhibit the tumor growth in αvβ3 integrin negative tumor 
cell, suggesting that the antiangiogenetic effect on the endothelial cells induced by this 










However, the peptide RGD4C contains disulfide bonds in its structure, which is susceptible to 
hydrolysis under reduced condition in cytoplasm, and result in inactive substance. Cyclic 
pentapeptide c(RGDfK) (Cilengitide) has emerged as an alternative to RGD4C for its good 
affinity and better water solubility than RGD4C. The in vitro cytotoxicity study revealed good 
growth inhibition of the breast cancer cell MDA-MB-435 (overexpressing αvβ3 integrin) (70). 
(Figure 1-3). Besides of doxorubicin, another front-line anticancer drug, paclitaxel, was also 
conjugated with integrin targeting bicyclic peptide E[c(RGDyK)]2 (71, 72). The activity of the 
conjugate was evaluated in metastatic breast cancer cell MDA-MB-435 and found comparable to 
the free paclitaxel in the cancer cell proliferation inhibition assay. cIBR and cLABL have also 
been conjugated to methotrexate (MTX) to target to LFA-1 integrin (73).  
 
          
Doxorubicin              Space linker            Targeting peptide 
Figure 1-3 Doxorubicin-peptide conjugate with formaldehyde space linker 
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Integrin ligands can also be conjugated with therapeutical biomacromolecules to target them to 
the specific intracellular site for their action. The conjugate of the bicyclic (ACDCRGDCFC) 
peptide with the antimicrobial synthetic peptide (KLAKLAK)2 showed significant tumor 
reducing effect and lowering in the lung metastasis burden (74). Another naturally occurring 
antimicrobial peptide also showed antitumor efficacy on B16 melanoma bearing syngenic mice 
after being coupled with integrin targeting peptide (RGD) (75). RGD peptide was also used to 
couple to endostatin, a endogenous antiangiogenetic protein, for more effective tumor inhibition 
(76). The cytokine protein TNFα (Tumor necrosis factor α) was shown to have better TNF 
receptor binding affinity and trigger apoptosis cascades after decorating with RGD integrin 
targeting ligand (77, 78). Using fusion protein technology, interleukin-12, interleukin-24, tTF 
(truncated tissue factor), or other tumor suppressing and/or apoptosis-inducing cytokines have 
also been fused with different integrin targeting ligands for antitumor and antiangiogenesis 
activity (79-81).   
 
1.3.2 Vascular targeted nanoparticle drug delivery 
Nanoparticulate delivery system surface modified with integrin targeting ligand is another 
approach to deliver therapeutical agents to targeted cancer cells or diseased organs. Meanwhile, 
the nanoparticulate delivery system is believed to increase the stability of the encapsulated or 
conjugated therapeutical molecules, improve the efficacy, and alleviate the undesired side-effect. 
And also, as tumor is featured by its leaky blood vessels and poor lymphatic drainage, 
nanoparticles can penetrate and accumulate into tumor via those leaky vessels by the enhanced 
penetration and retention (EPR) effect (82). To specifically target receptor overexpressing cancers 
or disordered cells, there are generally two classes of targeting: active targeting and passive 
targeting. Active targeting is programmed by engineering nanoparticle with cellular specific 
targeting moieties, whilst it is difficult to realize without passive targeting, in which 
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poly(ethylene glycol) (PEG) is normally chosen to attenuate the surrounding environment 
(commonly aqueous or body fluid) to the nanoparticles to protect them from protein absorption 
and also to prolong the circulation time after administration into the body (83). The most 
investigated nanoparticulate delivery systems are liposomes, polymeric nanospheres, micelles and 
polymersomes, etc. with a broad size range from several tens of nanometer to hundreds of 
micrometers. 
 
Amongst the integrin targeting ligands, RGD containing peptide decorated nanoparticulate 
delivery system is most extensively investigated, and fruitful results have been achieved through 
this strategy. For instance, RGD peptide was conjugated to the phospholipids with PEG as linker. 
The construct was then incorporated into liposome to realize both passive and active targeting 
functions. Murphy and co-workers had coupled cRGDfK peptide to PEGylated liposome 
encapsulating anticancer drug (doxorubicin) to target αvβ3 integrin expressing tumor vasculature. 
In two different animal models, this αvβ3 integrin targeting mediated delivery system resulted a 
15-fold increase in antimetastatic activity without any pronounced drug-associated weight loss as 
observed with systemic administration of the free drug (84). Xiong, et al .achieved high tumor 
accumulation and intracellular delivery of doxorubicin after conjugating synthetic RGD mimic 
compound with the drug-loading liposome in syngenic B16 melanoma mouse model. 
Administration of RGD mimic modified nanoparticle resulted in retarded tumor growth and 
prolonged lifespan compared with the non-modified one (85, 86). Similar RGD liposome 
modification strategies have also been used to deliver other anticancer drugs (e.g. 5-FU, 
paclitaxel) to malignant tumor bearing animals, and significant anti-primary tumor and 
antimetastatic  activities were achieved (87-89).  
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RGD decorated liposome was also used in combination therapy in which vascular disrupting 
agent (combretastatin) loaded RGD surface tethered liposome was combined with radiation 
therapy (90). This combination therapy resulted in lower drug dosage (from 80mg/kg of free drug 
to 14.5mg/kg equivalent in the drug loaded targeting nanoparticle), and better treatment outcome. 
Not just limited in cancer therapy, RGD modified liposomes have also been applied for other 
disease treatments, and good therapeutic results were achieved (91, 92). In addition to liposome, 
Gao’s group developed biodegradable polymeric micelles, a type of self-assembled nanoparticles 
from amphiphilic copolymers, with cRGD surface functionalization for targeted doxorubicin 
delivery (93). Later on, they further made this delivery system multifunctional by adding iron 
oxide nanoparticles in the system for simultaneous MRI imaging and drug delivery (94). 
 
Other integrin targeting micelle drug delivery systems with diverse compositions were also 
available (95, 96). Besides using RGD as integrin targeting ligand, Kim and co-workers also 
encapsulated RGD containing peptide in nanoparticle delivery system for antitumor therapy (97). 
In an in vivo study, the antiangiogenic peptide drug formulation of RGD - 5β-cholanic acid (HGC) 
markedly inhibited bFGF-induced angiogenesis and decreased hemoglobin content in Matrigel 
plugs. Intratumoral administration of RGD - HGC significantly decreased tumor growth and 
microvessel density compared to native RGD peptide injected either intravenously or 
intratumorally. Swenson et al. reported the liposomal delivery of a novel snake venom disintegrin, 
contortrostatin (CN) in an orthotopic human breast tumor xenograft model (98). This disintegrin 
modulates its interaction with integrins on tumor cells and angiogenic vascular endothelial cells. 
By incorporating CN into a liposomal delivery system, several advantages were identified as 1) 
CN in the liposomal delivery system had a significantly prolonged circulatory half-life compared 
with native CN; 2) CN in liposome was passively accumulated in the tumor; 3) had no platelet 
reactivity; and 4) was not recognized by the immune system. In their study, they demonstrated 
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that intravenous delivery of liposomal CN led to potent antiangiogenic activity in the in vivo 
tumor model.  
 
1.4 Conclusion 
The high occurrence and death rate of cancer has threatened human beings for many decades.  
Especially due to the metastatic character of many types of cancers, it is rather difficult to 
diagnose the tumor spreading in the initial stage of cancer, but it is too late to completely cure the 
patients when massive metastatic lesions occur. In the past decades, numerous therapeutic 
methods or tools have been designed to fight against the cancer metastasis. Various lines of 
evidences have demonstrated that angiogenesis in tumor is one of the culprits for cancer 
metastasis. And angiogenesis is a complicated process that many cytokines, growth factors, 
cellular signaling pathways are involved. Typically, the tumor endothelial cells, which are the 
basis for the tumor capillary formation, are highly associated in nearly all of the angiogenesis 
steps.  
 
Ever since Folkman proposed the concept of antiangiogenesis therapy in 1970s, and the 
continuous strive on the understanding of biological mechanisms, thousands of therapeutic agents 
for antiangiogenesis therapy have been developed. Although some of the drugs are already in the 
market or in late stage of clinical trials, they are just small fractions of such reported 
antiangiogenesis drugs. It is believed that a large number of antiangiogenesis drugs that 
ultimately fail the clinical trials may be attributed to the pharmacokinetic profiles and extreme 




The rapid advancing of nanotechnology has made great contribution in biomedical applications, 
especially in cancer research. Nanoparticles loaded with therapeutic agents could elongate the 
circulation time of drug in human body, accumulate anticancer drug at specific tumor sites, and 
alleviate the potential side-effects of drugs. In the field of antiangiogenesis, apart from the as-
stated features, nanoparticle would also target the antiangiogenesis drugs to specific steps 
involved in the angiogenetic progress. What is more important, nanoparticle may also enhance 
the therapeutic effects of drugs by combining the conventional chemotherapeutic drug with 
antiangiogenesis drug, due to the sensitization effects of some antiangiogenesis drugs to 
chemotherapeutic drugs or radiotherapeutics.   
Herein, we hypothesize that combination of anti-angiogenic drugs with chemotherapeutic drugs 
could present superior therapeutic effects to cancer versus anti-angiogenesis monotherapy with 
less side effects arising from traditional anti-cancer drugs by nanoscale drug delivery systems. To 
prove this hypothesis, we firstly investigated the cancer cell and highly proliferating endothelial 
cell uptake of RGD modified different active targeting nanoparticles, respectively. Secondly, we 
encapsulated drug cocktail into polyester matrix to study the combinatorial drug delivery system 
with RGD surface modification. Last but not the least, we studied the passive targeting ability of 
a novel temporal drug release micelle to antiangiogenesis, anticancer, and metastasis prevention 





Chapter 2  






Most cancers begin as localized diseases, but they are prone to spread to distant sites within the 
body. This adverse character makes many cancers incurable. The adhesion molecules were 
reported to play key roles in the regulation of cellular activation, migration, proliferation, survival, 
apoptosis, and differentiation (54). The overexpression of integrin receptors on some malignant 
cancer cells provides a distinct marker for targeted chemotherapeutical or diagnostic contrast 
agent deliveries. Typically, the Arg-Gly-Asp (RGD) peptide, which has high affinity to αvβ3 
integrin, has been applied in experimental studies to deliver either drugs (99), gene (100), or 
imaging agents (101) to the desired targeted sites.  
 
Nanoparticulate drug delivery system has been extensively explored in the past few decades, and 
the technology is rapidly advancing (102). Thus, the emerging nanomedicine in cancer therapy is 
popularly explored by many researchers (103, 104). Since most of the current chemotherapeutical 
drugs have notoriously undesirable side effects, which limit their further clinical application, 
novel drug delivery system aiming to overcome the intrinsic side effects arising from the 
anticancer drugs are urgently needed. Site specific targeting nanoparticles are evidenced to be a 
promising tool to effectively deliver anticancer drugs (105, 106). Some targeting peptides, like 
RGD, are also considered as promising ligands for targeted delivery payloads to specific 
malignant cancer cells. Nevertheless, active targeting function is hardly successfully 
accomplished until the passive targeting function is realized (107). Poly(ethylene glycol) (PEG) 
for passive targeting goal is much favored by many researchers due to its biocompatibility, 
degradability, and less protein interaction characters in animal body (108). Thus, nanoparticles 




Poly(lactic-co-glycolic acid) (PLGA) was regarded as biological friendly and degradable 
materials in biomedical application. And many investigations have been done to use PLGA as 
matrix material to deliver drug, gene or imaging agents. Nevertheless, most of the PLGA micro- 
or nano-particles were short of either passive or active targeting function, or both of them. Also, 
the inevitable burst release effect involved in PLGA based nanoparticulate delivery systems sets 
another hurdle for its clinical application.  
 
Herein, we investigated the potential of RGD modified nanoparticle with active and passive 
targeting function for effective targeting different types of cancerous cells so as to induce cancer 
cell apoptosis by conjugated chemotherapeutic agent, doxorubicin. In this study, PLGA was 
chemically conjugated with doxorubicin, a widely used anticancer drug, before it was fabricated 
into nanoparticles to avoid the burst effect commonly observed in nanoparticles physically loaded 
with therapeutic drugs (109, 110). The physicochemical properties of the nanoparticles were 
characterized. The selective uptake of these Doxo-PLGA-PEG-cRGD nanoparticles by different 
cancer cells was investigated via confocal laser scanning microscope (CLSM). The potency to 
induce apoptosis in malignant cancer cell was initially evaluated by DNA fragmentation assay 
and western blot assay. 
 
2.2 Materials and methods 
2.2.1 Materials 
PLGA (RG503H) was obtained from Boehringer Ingelheim (Germany). Amino-Poly (ethylene 
glycol)-Carboxylic acid (NH2-PEG-COOH) with M.W. 2000 was purchased from NOF 
Corporation, Japan. Poly (ethylene-maleic anhydride) (PEMA) was purchased from Polysciences, 
Inc. N-hydroxysuccinimide (NHS), N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide 
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hydrochloride (EDC), 4-Nitrophenyl chloroformate (pNC), pyridine, acetone, triethylamine 
(TEA), N,N-Dimethylformamide (DMF), 3-(4,5-dimethylthiaol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT), Dulbecco's Modified Eagle's Medium (DMEM) and RPMI-1640 medium were 
purchased from Sigma Chemical, Co (St. Louis, MO, U.S.A.). All other chemicals were of 
analytical grade. Doxorubicin hydrochloride was purchased from Woo-Shin Medics, Co. Korea. 
B16F10 mouse melanoma cells, DU145 human prostate carcinoma cells, MDA-MB-231 human 
mammary carcinoma cells, and MCF-7 human mammary carcinoma cells were obtained from 
American Type Culture Collection (Rockville, MD). Antibodies used in western blot were 
purchased from Cell Signaling Inc. All other chemicals used in this study were obtained from 
Sigma, Co. (MO. U.S.A.). Deionized water (Millipore, Bedford, MA, U.S.A.) was used thorough 
the entire study. 
 
2.2.2  Conjugation of doxorubicin to PLGA 
PLGA (Resome® 503H), with a lactide / glycolide molar ratio of 50/50, and free hydroxyl and 
carboxylic groups at its terminal ends, was used. The preparation procedure was similar to a 
previous study (111) with minor modification. Briefly, 0.5 g of PLGA was dissolved in 10 ml of 
methylene chloride and activated by the addition of 26.3 mg of p-nitrophenyl chloroformate and 
18 μL of pyridine to the solution, kept in an ice bath at 0 °C. After isolation, 0.3 g activated 
PLGA was dissolved in 3 mL of dimethylformamide (DMF) and reacted with 12.9 mg of 
doxorubicin with 15.5 μL of triethylamine for 24 hours at room temperature under nitrogen 
atmosphere. The final conjugated product was precipitated by excess cold ether, and dried under 
vacuum. The efficiency of doxorubicin conjugated to PLGA was determined by dissolving the 
conjugated products in DMSO, and the amount of doxorubicin was quantitated by UV/VIS 
spectrometry (Perkin-Elmer, Japan) at 480 nm.  
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2.2.3 Preparation of PLGA-doxorubicin (PLGA-Doxo) nanoparticles 
PLGA nanoparticles were prepared by a solvent diffusion method (112). 50 mg of PLGA-
doxorubicin conjugate was dissolved in 3.5 mL of acetone, and the organic solution was added to 
0.2% PEMA (35 mL) through a syringe pump (20 mL/h) under stirring at 1,500 rpm in a fume 
hood to evaporate acetone overnight. The nanoparticles produced were collected and washed 
three times with deionized water, and followed by ultrafiltration (Millipore, Amicon®) at 4,000 
rpm for 45 min. Finally, the nanoparticles were dispersed in deionized water to give the desired 
concentration.  
 
2.2.4 Synthesis of Doxo-PLGA-PEG-cRGD nanoparticles 
10 mL of the prepared PLGA-Doxo nanoparticle solution was diluted with 0.1 M MES (pH 6.0), 
and then subject to ultrafiltration, and washed with 0.1 M MES twice.  The precipitated 
nanoparticles were collected, and finally suspended in 0.1 M MES solution. 153 mg EDC, and 
230 mg sulfo-NHS were added into the nanoparticle suspension. The mixture was incubated for 2 
h at room temperature. After washing off the impurities from the suspension with PBS buffer (pH 
7.4), 50 mg NH2-PEG-COOH with 6.9 μl TEA was introduced into the activated PLGA-Doxo 
nanoparticle suspension, and incubated for 4 h. The resultant product was washed three times 
with PBS (pH 7.4) and separated by ultrafiltration. Finally, the nanoparticles were dispersed in 
PBS buffer to the desired concentration.  
 
The prepared PLGA-PEG nanoparticles were once again diluted, washed, and suspended in 0.1 M 
MES (pH 6.0) for another cycle EDC/NHS chemistry for conjugation of cRGD peptide. The 
activated PLGA-PEG nanoparticle suspension was mixed with 1.5 mg cRGD (Anaspec, U.S.A.), 
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and incubated overnight for complete reaction. After that, the synthesized Doxo-PLGA-PEG-
cRGD nanoparticles were dispersed in PBS (pH 7.4) buffer to the desired concentration.  
 
2.2.5 Characterization of nanoparticles 
The mean size, polydispersity and zeta potential of the NPs were determined by size analyzer 
(Zetasizer 3000 HSA, Malvern Instruments Ltd., England).The encapsulated drug in the NPs and 
drug encapsulation efficiency were determined via spectrometry under 480 nm with microplate 
reader. The spectrometry was calibrated with different concentrations of doxorubicin dissolved in 
DMSO. The cRGD peptide conjugated on the nanoparticle surface was calculated with the 
established fluorescamine method (113). The micro-structure of the NPs was visualized by 
transmission electron microscopy (TEM) (CM10, Microscope Philips) with 2% phosphotungstic 
acid staining. 
 
2.2.6 Cytotoxicity assay 
The cell proliferation assay was conducted based on tetrazolium dye (MTT) method. MDA-MB-
231, B16F10 and MCF-7 cells were grown in DMEM medium, and DU-145 cells were grown in 
RPMI-1640 medium. All the cell culture mediums were supplemented with 10% FBS, 0.1% 
nonessential amino acids, and 100 μg/ml penicillin, and 100 unit/ml streptomycin. The cells were 
separately seeded into 96-well plates at the density of 5x103 cells/well and incubated at 37 oC, 5% 
CO2 for 24 hours before experiment. NPs were diluted with corresponding culture mediums to 
different concentrations. Pure drug was used as control. After washing the cells with PBS buffer 
three times, different concentrations of samples were added to the respective cells at 200 μL/well. 
After incubation for 48 h, the cells were washed with PBS buffer three time, and further 
incubated with 120 μL/well MTT solution (0.5 mg/ml) for another 3 h. At the end of incubation 
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time, the excess MTT solution was removed, and the formed formazan crystals were dissolved by 
DMSO. The resultant solution was measured at 570 nm with DMSO as blank (n =6). 
 
2.2.7 Cell uptake and binding affinity assays 
Since doxorubicin is intrinsically fluorescent, this facilitated the visualization of the uptake of the 
doxorubicin formulated NPs into cells under confocal laser scanning microscope (CLSM). To 
observe the internalization of NPs under CLSM, the desired cells were cultured over night in Lab-
Tek® eight well chambers (Nalgene, Nunc Inc., Denmark; seeded at density of 2.0x104 cells/well). 
Then, the cells were washed with 3 x 0.2 mL/well of PBS and equilibrated with 0.2 mL/well of 
HBSS/HEPES at 37 oC for 30 min. Freshly prepared nanoparticles were diluted with 
HBSS/HEPES to give the desired concentrations. After balancing the cells with HBSS/HEPES, 
the medium was then aspirated, and 200 μL/well NPs solution was added into each well. At 
different time points, the uptake experiment was terminated by aspirating the test samples and 
washing the cell monolayers with 0.2 mL/well of ice-cold PBS three times. Then, each cell 
monolayer was fixed with methanol / acetone (1:1, v/v) followed by nuclear staining with DAPI 
(20 μmol/mL). The cells were observed under CLSM (Zeiss, Heidelberg, Germany) with 
excitation filter at 488 nm, long band pass emission filter 520 nm for internalized drug; and UV 
excitation for DAPI staining. 
 
2.2.8 DNA fragmentation assay 
DNA fragmentation assay was performed on MDA-MB-231 cells, according to the procedure 
previously described procedure (114) with minor modification. Cells were grown in DMEM 
medium before treatment. On the experimental day, cells were treated with 1) cell culture 
medium; 2) pure drug dissolve in cell culture medium (5μg/ml), and 3) Doxo-PLGA-PEG-cRGD 
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nanoparticle with equivalent drug concentration in culture medium. After 48 hours incubation, 
cells were washed with ice-cold PBS three times and collected by trypsinization. The cell pellets 
were re-suspended in 0.5 ml lysis buffter (1% Triton X-100 with 20 mM EDTA and 50 mM Tris-
HCl, pH 7.4). The supernatant was subjected to 5 mg/ml RNase A at 56 oC for 2 hours, followed 
by incubation with 2.5mg/ml Proteinase K for at least 2 h at 37 oC. After addition of 0.5 volume 
of 10 M ammonium acetate, DNA was precipitated with 2.5 volume of absolute ethanol at -20 oC 
overnight. Then, the DNA was collected via high speed centrifugation, and rinsed with 70% 
ethanol once, and the DNA pellets were collected after centrifugation for 25 min at 14,000 rpm. 
The retrieved pellet was dried in a SpeedVac to remove the residual ethanol. The resultant DNA 
was dissolved in TE buffer (10mM Tris-HCl and 1mM EDTA, pH 8.0), followed by 1% agarose 
gel electrophoresis, and stained with ethidium bromide.  
 
2.2.9 Western blot analysis 
Western blot analysis was conducted on MDA-MB-231 cells. Protein was extracted from cells 
with lysis buffer (1% Triton X-100 with Proteinase inhibitor cocktail) at 4 oC. The extracted 
proteins were separated with SDS-PAGE and transferred to PVDF membrane. The membrane 
was blocked by TBS buffer containing 5% skim milk over night. After washing with washing 
buffer (TBS buffer with 0.1% Tween 20), the membrane was incubated with primary antibodies 
specific for cleaved, non-cleaved caspases 3 and actin at room temperature for 2 h, and 
corresponding secondary antibodies for 1 h. After extensive washing, bands were detected by 




2.2.10 In vitro drug release 
In vitro drug release profile of Doxo-PLGA-PEG-cRGD nanoparticles was determined by loading 
1 ml of original nanoparticle suspension into dialysis tubing (M.W. 12,000), which was 
submerged into 10 ml PBS (pH 7.4), and shaken at 37oC, 100 rpm in a water bath. The released 
drug was retrieved at pre-determined time points, and analyzed by fluorescence spectrometry 




2.3.1 Conjugation of doxorubicin to PLGA 
The conjugation of doxorubicin to biodegradable, biocompatible polymer, PLGA, has been 
reported to be effective in enhancing the drug bioavailability, minimizing the burst release effect 
and substantially enhancing the loading efficiency (109-111). Fig. 2-1 shows the schematic route 
of doxorubicin-PLGA conjugation by carbamate linkage between the hydroxyl group on PLGA 
and amine group on doxorubicin. The available carboxyl groups were ready for the subsequent 
linkage with the primary amine groups on PEG chain after formation of nanoparticles. The extent 
of conjugation of doxorubicin to the PLGA was determined to be around 2.93% in weight ratio.  
 
Figure 2-1. Scheme of conjugating doxorubicin to PLGA 
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2.3.2 Synthesis and characterization of Doxo-PLGA-PEG-cRGD nanoparticle 
The schematic procedure of synthesis of Doxo-PLGA-PEG-cRGD nanoparticles is presented in 
Fig. 2-2. In the preparation of initial PLGA NPs, PEMA was used as surfactant instead of the 
conventionally used poly(vinyl alcohol) (PVA) to increase the surface carboxyl groups. 
Saltzman’s group had utilized this surfactant to conjugate antibody onto PLGA NPs’ surface, and 
suggested that PEMA did not significantly change the characters of conventional PLGA NPs 
prepared with PVA (115) . The surface modification with PEG and cRGD makes the PLGA 
nanoparticles more functional than the conventional unmodified PLGA nanoparticles. 
 
Figure 2-2. Schematic route of preparation of Doxo-PLGA-PEG-cRGD nanoparticles 
The characteristics of PLGA nanoparticle (including conjugated doxorubicin) (PLGA-Doxo) and 
Doxo-PLGA-PEG-cRGD nanoparticle are summarized in Table 2-1. It is obvious that after two 
steps of conjugation to the PLGA-Doxo NPs surface with PEG and cRGD, the mean size of NPs 
increased, and also the polydistribution became slightly wider. The surface charge of NPs 
dramatically increases from -51.7+/-3.1 to -18.9+/-2.4 mV, which was attributed to the surface 
modification with PEG and cRGD, both of them consumed the carboxyl groups on the 
nanoparticle’ surface. However, the surface modification did not significantly change the drug 
encapsulation efficiency (E.E.) and encapsulation capacity (E.C.), indicating that the formulation 
and series of modification procedures did not lead to dramatic drug loss, whilst the minor 
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decrease of both E.E. and E.C. may be owing to the loss of unencapsulated doxorubicin 
conjugates available on particle surface, or the minor amount of doxorubicin cleaved from PLGA 
during the preparation period, due to the slow hydrolysis of liable glycol block on PLGA 
backbone in aqueous environment.      
Table 2-1 Physical characteristics of PLGA based nanoparticles (mean +/-SD, n=3) 








E. C. * 
(ug drug / mg NP) 
cRGD quantity 
(nmol peptide/ mg 
NPs) 
PLGA-Doxo 366.6 +/-3.1 0.158 -51.7+/- 3.1 88.3% 15.32 +/-1.2 N/A 
Doxo-PLGA-PEG-
cRGD 
423.0 +/-16.6 0.189 -18.9 +/- 2.4 87.2% 14.99 +/-2.4 0.15+/-0.03 
*E.E.= Encapsulation Efficiency: drug encapsulated in the NP to initially added drug into the 
formulation; *E.C.= Encapsulation Capacity: the amount of drug encapsulated into milligram of 
NP. 
 
The morphology of as-prepared PLGA-Doxo and Doxo-PLGA-PEG-cRGD nanoparticles were 
characterized by TEM, respectively. It can be seen from Fig. 2-3 that both types of NP were quite 
uniform and well-dispersed with low size distribution, similar to the results characterized by 
dynamic light scattering method (zetasizer measurement). Also, both NPs were solid, spherical 
nanoparticles with smooth surface. 
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 Figure 2-3. TEM images of PLGA-Doxo nanoparticles (a) and Doxo-PLGA-PEG-cRGD 
nanoparticles (b). Insets are the corresponding dynamic light scattering results obtained from 
measurement of Zetasizer. 
 
2.3.3 Cytotoxicity of NPs to various malignant cancer cells 
The cytotoxicity effects of both pure doxorubicin and drug containing nanoparticles were 
conducted by an established MTT assay (Fig. 2-4). The drug concentration range was from 
0.005μg/ml to 50μg/ml. Equivalent amounts of drug encapsulated in drug containing 
nanoparticles were adjusted to the equivalent concentrations by the corresponding cell culture 
medium. Cytotoxicity of the drug free NPs was also investigated at the highest NPs concentration 
used in the MTT assay.    
In term of IC50 values, the three integrin expressing cancer cells retained different sensitivity to 
pure doxorubicin and Doxo-PLGA-PEG-cRGD NPs, respectively. With pure doxorubicin, 
B16F10 cells showed the most sensitivity (IC50=0.09 μg/ml), whilst DU145 (IC50=0.71 μg/ml) 
and MDA-MB-231 (IC50=0.41 μg/ml) cells presented similar, but lower sensitivity. However, this 
cytotoxicity trend dramatically changed when cells were treated with Doxo-PLGA-PEG-cRGD 
nanoparticles. After incubation with NPs, the NPs showed the most cytotoxitic to MDA-MB-231 
(IC50=0.63 μg/ml), median with B16F10 (IC50=1.13 μg/ml), and the lowest with DU145 
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(IC50=2.29 μg/ml). It can be seen that for all the three integrin expression cells, the cytotoxic 





Figure 2-4. Cytotoxicity results of Doxo-PLGA-PEG-cRGD nanoparticles or doxorubicin to (a) 
B16F10 cells, (b) DU145 cells, and (c) MDA-MB-231 cells. 
 
2.3.4 Cell affinity assay 
Affinity of different malignant cells to pure drug, modified and non-modified NPs was 
investigated by CLSM. Fig. 2-5 (a-i) shows the uptake of Doxo-PLGA-PEG-cRGD NPs at 
various time points by different cancer cells. Since B16F10 (116, 117), DU145 (118) and MDA-
MB-231(119) cells all express αvβ3 integrin on cell membranes, Doxo-PLGA-PEG-cRGD NPs 
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should be selectively recognized by these integrin expression cancer cells upon exposure, and 
underwent endocytotic pathway into cytoplasm. As shown in Fig 2.5 (a-i), the uptake of NPs into 
cytoplasm followed a time-dependent manner. It was noted that the uptake of NPs was not 
significant after 2-hour incubation, compared to that at 0.5 hour. The most significant uptake of 
NPs was observed at 4 hours incubation in B16F10, DU145 and MDA-MB-23 cells. Because of 
the lacking of integrin on MCF-7 cell membrane (120), the uptake of cRGD modified NPs into 
these cells was few over the 4-hour incubation period, except for few non-specific association to 
cells after 4 hours .  
 
2.3.5 In vitro drug release 
The in vitro drug release profile of Doxo-PLGA-PEG-cRGD NPs is shown in Fig. 2-6. The drug 
released from the polymer matrix was in a sustained release manner. The “burst release effect” 
commonly associated with micro- or nanoparticle delivery system was, to some extent, avoided 
during the first several hours’ release period. 
 
2.3.6 Cell apoptosis induced by Doxo-PLGA-PEG-cRGD NPs 
Typical apoptotic cell death can be detected by various morphological and biochemical 
characterization of cell death. In this study, agrose gel electrophoresis and western blot were 
employed to detect Doxo-PLGA-PEG-cRGD NPs induced apoptosis of the cancer cells. DNA 
fragmentation effect of Doxo-PLGA-PEG-cRGD NPs was determined on MDA-MB-231 cell line. 
The respective pure doxorubicin and NPs were adjusted to contain 5 μg/ml of doxorubicin; and 


























d  e f
g  h i
j  k l
38 
 
Figure 2-5. CLSM results of cellular uptake of Doxo-PLGA-PEG-cRGD nanoparticle in 0.5, 2 
and 4 hours incubation of (a-c) B16F10 cells, (d-f) DU145 cells, (g-i) MDA-MB-231 cells, and 
(j-l) MCF-7 cells. 
 
 
Figure 2-6. In vitro drug release profile of Doxo-PLGA-PEG-cRGD nanoparticles over 12 days at 
37oC, 100 rpm in shaking water bath. Results are represented in triplicate. 
In Fig. 2-7, the cells treated with NPs were shown to have more lower-molecular weight (LMW) 
DNA fragments that were resolved at the bottom of the agrose gel. In contrast, the cells treated 
with doxorubicin alone had more higher-molecular weight (HMW) DNA fragments found close 
to the loading well on the gel. Fig. 2-8 shows the western blot results in which the Doxo-PLGA-
PEG-cRGD NPs treated group showed higher cleaved caspase 3 expression. 
 
2.4 Discussion 
Many patients undertaking chemotherapy are suffering from serious side-effect arising from the 
anticancer drugs, and some may die because of the side-effect of drugs rather than the cancer 
itself. Thus, it entails intelligent design of drug delivery system so as to selectively target the 
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conventional chemotherapeutical drugs to the malignant tumor cells with high delivery efficiency 
and good efficacy so at to overcome the notorious side effects commonly associated with most 
 
1    2   3   4
 
Figure 2-7. DNA fragment results from agrose gel electrophoresis. Lane 1: DNA ladder; Lane 2: 
MDA-MB-231 cells treated with cell culture medium; Lane 3: MDA-MB-231 cells treated with 
doxorubicin; Lane 4: MDA-MB-231 cells treated with Doxo-PLGA-PEG-cRGD nanoparticles. 
 
 
          NPs      Doxo     Ctl 
Figure 2-8. Western Blot results: NPs: Doxo-PLGA-PEG-cRGD nanoparticles; Doxo: 
doxorubicin; Control: culture medium. 
 
anticancer drugs. Integrin, like αvβ3, has been extensively investigated to target many malignant 
cancer cells or endothelial cells for delivering cytotoxic drugs (99-101, 121, 122). Besides, 
integrin also has profound impacts in angiogenesis and metastasis of many cancers (84). As one 
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of the conventional chemotherapeutical drugs, doxorubicin, an anthracycline antibiotic, is widely 
used clinically. Despite its good efficacy for treatment of various cancers, doxorubicin has severe 
short- and long-term side effects mostly associated with bone marrow and myocardial 
cytotoxicity (123, 124). Thus, doxorubicin conjugates are believed to hold promise to overcome 
the side effects, and enhance drug efficacy to cancers. It was reported that doxorubicin conjugated 
novel targeting peptide had significantly improved the therapeutic efficacy (124), and water 
soluble poly(N-(2-hydroxy-propyl)methacrylamide) (HPMA) polymer based conjugates has also 
been extensively studied (125-128), and some are under phase I clinical evaluation (125, 129). 
RGD peptide, one of the small bioactive molecules, is typically favored by many researchers as 
targeting ligand to deliver pay-loads to targeted sites (112, 130). 
 
Nowadays, various PLGA based drug/gene delivery systems with a variety of ligands have been 
investigated, whereas few reports have focused on fabrication of PLGA NPs with both active and 
passive targeting moieties simultaneously for treating malignant cancers. In this study, we 
fabricated the PLGA based doxorubicin delivery system with both passive and active targeting 
functions for malignant integrin expression cancer cells. PEG (2000 M.W.) was chosen to realize 
the passive purpose, as PEG was reported to have the least protein interaction in animal body, 
was able to prolong the circulation period of pharmaceuticals, and was still functionable at the 
distal end (131-134). The molecular weight of 2000 Dalton was chosen, as PEG of higher 
molecular weight might hinder the cRGD active targeting function (120). The dynamic light 
scattering and TEM analysis showed that the as-synthesized Doxo-PLGA-PEG-cRGD NPs were 
uniform and well-dispersed, both properties are prerequisites for drug delivery systems suitable 
for clinical applications. Doxorubicin has moderate water solubility, whereas PLGA is rather 
hydrophobic. Thus, it is difficult to incorporate doxorubicin into PLGA NPs in high efficiency. 
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Conjugation of doxorubicin to one of the distal ends of PLGA significantly enhanced the loading 
efficiency from less than 1% (135) to 87.2% as found in this study. 
 
The different cytotoxic effects of Doxo-PLGA-PEG-cRGD NPs to various malignant integrin 
expression cancer cells were probably caused by the different integrin receptor expression levels 
on the cell membranes, with MDA-MB-231 the highest and DU145 the lowest (136-139), leading 
to different uptake efficiency of NPs. Also, the particulated doxorubicin delivery system altered 
the uptake of doxorubicin into cytoplasma from diffusion for pure doxorubicin aqueous solution 
to endocytosis pathway for doxorubicin containing NPs. What’s more, with the cRGD 
modification on NPs surface, the threshold of cytotoxic onset may be changed, too.  The inherent 
different cellular sensitivity to doxorubicin also influenced the resultant IC50 values.  As reported 
by other researchers (111), the conjugation of doxorubicin to PLGA polyester led to 
compromised cytotoxic effect to cancer cells (Fig. 2-4), yet Doxo-PLGA-PEG-cRGD showed 
least compromised efficacy to MDA-MB-231 cells, which may result from the higher integrin 
expression level in that cell line facilitating the uptake of NPs into cytoplasm. 
Results from CLSM (Fig. 2-5) revealed that Doxo-PLGA-PEG-cRGD NPs were preferred to be 
up-taken by MDA-MB-231 and B16F10 cells that had overexpressed integrin on their cell 
membranes. However, the uptake efficiency became static for both cells at a longer incubation 
time (no apparent difference in uptake after 4-h incubation with NPs); this might be due to 
saturation of the cellular surface receptor for NPs.  
 
The DNA fragmentation phenomenon is involved in most apoptotic conditions. Cells undergoing 
apoptosis process often produce short DNA fragments as indicated in our result (Fig. 2-7).  Doxo-
PLGA-PEG-cRGD NPs showed the most potency to induce dramatic DNA fragmentation 
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compared with doxorubicin alone. Cysteine proteases of the caspase family also play vital roles in 
the execution of apoptosis. Amongst the caspase family, caspase 3 acts as executor in apoptosis, 
leading to series of subsequent apoptotic signaling pathways (140). Fig. 2-8 shows that higher 
activated caspase 3 expression level was found in the cells treated with the Doxo-PLGA-PEG-
cRGD NPs. Therefore, the results from DNA fragmentation assay and western blot confirmed 
that Doxo-PLGA-PEG-cRGD NPs were able to deliver chemotherapeutical drugs selectively to 
the integrin expression cancer cells and induce apoptosis in these cells.  
 
Although the cytotoxic efficacy of doxorubicin was compromised after conjugation to PLGA, the 
selective targeting property and the sustained drug release profile of the doxorubicin NPs could 
improve the efficacy of the drug in vivo. The release kinetics of doxorubicin from the formulation 
was in zero-order (R2=0.97), in the range from 12 h to 12 days (Fig. 2-6). The release mechanism 
was assumed to be due to a combination of chemical degradation and diffusion release (111). 
 
2.5 Conclusion 
In this study, two independent approaches that conjugating doxorubicin to PLGA and mounting 
active and passive targeting moieties with PEG and cRGD onto to the NPs were adopted to 
fabricate the Doxo-PLGA-PEG-cRGD NPs. The NPs synthesized in this study were proven able 
to effectively target doxorubicin to malignant integrin expression cancer cells, and showed 
profound apoptotic induction effect to those cells. Although the drug efficacy to cancer cells was 
compromised after conjugation with PLGA, the resultant sustained release behavior and the 
property of selective uptake of the NPs by cancer cells could still make Doxo-PLGA-PEG-cRGD 





In vitro evaluation of vascular targeted nanocapsule with sequential 





Efficient drug delivery system plays a vital role in the clinical success of chemotherapy (141, 
142). Over the past decades, numerous efforts have been dedicated to develop effective drug 
delivery vehicles so as to fulfill the requirements in drug discovery and clinical application (143, 
144). Amongst those developed biocompatible and degradable delivery vehicles, nanoparticles 
with surface modification of cell specific targeting moieties have been shown great potential in 
cancer therapy by orienting the anticancer drugs to cancerous cells (131, 145). These systems 
enhance the drug accumulation at specific tumor site, and more importantly, reduce the 
notoriously side-effects commonly associated with most chemotherapeutic drugs (83).  
 
Most of the current targeted drug delivery systems have been designed for targeting specific cell 
surface receptors that were overexpressed on cancerous cells (146). This cancer cell specific 
targeted strategy may have the inherent limitation as this strategy could only be applied to limited 
number of cancer cell types with overexpression of those specific surface receptors. In addition, 
some cancer cells, like MCF-7 breast cancer cell can hardly be detected with the cell membrane 
receptors that significantly distinguish them from other common organs. That would hamper the 
targeted drug delivery to these cancer cells.  
 
It is well-known that tumor growth depends much on the oxygen and nutrients supplied by tumor 
blood vessels. And tumor vasculatures are universally available in nearly all tumor types (147). 
Hence, targeting medicine directly to tumor vasculature instead of tumor cells could provide an 
alternative approach to fight against cancers. This concept has been proved by researchers who 
reported that integrin αVβ3 targeted delivery of therapeutic gene to integrin knock-out human 
melanoma cells could target the tumor vasculature and significantly result in tumor 
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regression.(148)  As proposed by Folkman (40), antiangiogenetic therapy, in which angiogenetic 
tumor vasculature could be interrupted or blocked by drug interventions so as to induce tumor 
dormancy, sets a solid foundation for this tumor vasculature targeted therapy. However, it was 
evidenced that tumor angiogenesis is a comprehensive result of multiple pathways, the composite 
mechanism of which would limit the therapeutic effects from single antiangiogenesis therapy 
(149). What is more, due to their plasticity, tumor could evade the single targeted therapeutic 
approach designated to control proliferation and survival of tumor cells (150). Thus, a tumor 
vasculature targeted combinatorial approach that sequentially releases the antiangiogenetic agent 
aiming to shut-down tumor vasculature, followed by cytotoxic drug exposure to the tumor cells 
could lead to the most effective cancer treatment result. 
 
After confirming the cancer cell targeted ability of nanoparticle in Chapter 2, here, we designed a 
novel universal tumor vasculature targeted double self-assembly core-shell nanocapsule (cNC) 
aiming to sequentially disrupt tumor vasculatures by vascular disrupting agent (combretastatin 
A4) (CA4), followed by apoptosis induction to tumor cells through cytotoxic drug (paclitaxel) 
(PTX). RGD peptide was used as the vascular targeting ligand as the proliferating tumor vascular 
endothelial cells overexpress integrin receptors, αVβ3 and αVβ5, on cell membrane (151).  
 
3.2 Materials and methods 
 
3.2.1. Preparation of Paclitaxel loaded PLGA core 
The paclitaxel (PTX) loaded PLGA core was prepared by a nanoprecipitation method according 
to a recent publication with minor modification (152). The PLGA polymer precipitated to form a 
hydrophobic core to encapsulate the poorly water-soluble PTX. Lecithin and DSPE-PEG 
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conjugates self-assembled around the PLGA core to form a lipid monolayer covered by a 
hydrophilic PEG shell. Briefly, 50 mg of poly(lactic-co-glycolic acid) (PLGA) and 5 mg of PTX 
were dissolved in 10 ml acetonitrile to form organic mixture. 6 mg lecithin (Lipoid GmbH) and 6 
mg DSPE-PEG2000 (Avanti Polar Lipid) were dissolved in 5% ethanol aqueous solution at 65oC. 
Then, the as-formed organic mixture was dropped into the lipid containing ethanol aqueous 
solution with magnetic stirring. The resultant mixture was subject to vortex to disperse the 
organic droplet evenly and help the lipid self-assemble process, followed by magnetic stirring for 
6 hours to evaporate the organic phase and form the nanoparticles. The resultant nanoparticle was 
washed three times with water by ultracentrifugation (Millipore, MWCO= 10,000) at 4000 rpm 
for 20 min for each time.  
 
3.2.2. Preparation of core-shell nanocapsule 
A further lipid bilayer self-assembled around the above PEG coated PLGA nanoparticle as a shell 
with the objective to load a second drug in the lipid bilayer. The formed lipid bilayer would have 
PEG polymers with carboxyl ending groups protruding from its surface to the surrounding 
aqueous environment. To fabricate the core-shell nanocapsules, 10.5 mg distearoyl-sn-glycero-
phosphocholine (DSPC) (Avanti polar lipid), 10.3 mg cholesterol, 6 mg DSPE-PEG2000 
(carboxyl ending group) (Avanti polar lipid) and 10 mg combretastatin A4 (CA4) were co-
dissolved in 5 ml chloroform in a round bottom flask. And the 5 ml chloroform was evaporated 
with rotary evaporator (Buchi) to form a lipid film in the flask. And the as-dried film was 
maintained in the low pressure condition for 1 h. Then, 1ml PLGA loaded PLGA core suspension 
was added into the lipid film flask, and agitated at 250 rpm under 65oC for another 1 h. After that, 
the resulting suspension was extruded through 200 nm polycarbonate membrane with syringe 
extruder at 65oC for 10 rounds.  
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3.2.3. Conjugation of RGDfK peptide to the nanocapsule 
To conjugate RGDfK peptide to the PEG with carboxyl ending on the surface of the lipid bilayer, 
the above resultant nanocapsule was diluted with appropriate volume of 5 ml MES (pH 6.0) 
buffer, and incubated with 0.1M EDC/0.25M NHS for 1 h, followed by ultracentrifugation twice 
with PBS as washing buffer. Then RGDfK peptide was added into the activated nanocapsule 
solution, and incubated overnight. Then the resultant targeted nanocapsule was purified with 
ultracentrifugation 3 times.  
 
3.2.4. In vitro drug release from the core-shell nanocapsule 
1ml of the concentrated nanocapsule suspension was sealed in a dialysis tubing (MWCO = 
12,000), which was incubated in 10 ml PBS (pH 7.4) at 37oC, 100 rpm shaking speed. At 
designated time interval, 200 μl of incubation medium was drawn and analyzed by HPLC method 
at 1 ml/min flow rate, acetonitrile/water (50:50) with 0.1% TFA as mobile phase. The PTX and 
CA4 could be detected simultaneously at wavelength of 227 nm and 295 nm, respectively.  
 
3.2.5. Cell apoptosis assay 
The cell apoptosis assay was conducted by CellTiter 96 AQueous Non-Radioactive Cell 
Proliferation Assay (Promega). Human breast cancer cells, MCF-7, were cultured in 96-well plate 
at cellular density of 5x103/well in Dulbecco’s modified eagle medium (DMEM) supplemented 
with 10% fetal bovine serum, 0.1% nonessential amino acids, and 100 μg/ml penicillin, and 100 
unit/ml streptomycin. The cultured cells were incubated at 37oC, 5% CO2 for 24 hours before 
experiment. The PTX containing PLGA core was diluted with cell culture medium to designated 
concentration, and 100 μl of such solution was added into each well. After 48 h incubation, 20 μl 
of CellTiter 96 AQueous Non-Radioactive Cell Proliferation Assay solution was added to each 
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well and incubated for another 2 h before measure at 490 nm with multiplate reader (TECAN). 
PLGA core without PTX was also evaluated as negative control. Data were presented as mean ± 
SD (n=6).  
 
3.2.6. Immunofluorescence staining of tubulin disruption  
To reveal the ability of CA4 lipid formulation to disrupt endothelial microtubule cytoskeleton, 
cultured human umbilical vascular endothelial cells (HUVEC) were incubated with CA4 lipid 
formulation (equivalent to 0.25μM drug) for 24 h. After the incubation, the cells were fixed with 
acetone/methanol (1:1) mixture for 10 min at -20oC, followed by sequential incubation with anti-
β-tubulin primary antibody (Sigma), and corresponding FITC coupled secondary antibody (Pierce 
Biotechnology). Fluorescent images were taken using Nikon Eclipse TE200 inverted microscope 
equipped with cooled CCD camera. 
 
3.2.7. Cellular uptake of the nanocapsule 
The cellular uptake of nanocapsule by HUVEC was evaluated by confocal laser scanning 
microscope (CLSM). HUVECs were seeded in Lab-Tek® chambers (Nalgene, Nunc Inc., 
Denmark) at density of 2 x 104 per well, and allowed to attach for 24 hours. 6-coumarin labeled 
nanocapsule was diluted with serum-free cell culture medium to 100μg/ml before adding to the 
cultured cells. After the designated time points (20min, 1, 2, and 6 h), the cells were washed three 
times with PBS, and fixed with 4% paraformaldehyde and Triton X-100 before staining with 
Texas Red® conjugated phalloidin, then the cells were washed with PBS, followed by adding 
DAPI to stain the cell nuclei. Optical images were obtained using Olympus Flowview FV1000 
Confocal laser scanning microscope. A 60x objective aqueous lens was used with 488nm argon, 
543nm HeNe and 405nm diode lasers.  
49 
 
To investigate the inhibitory effect of free RGDfK peptide to the cellular uptake of RGDfK 
modified nanocapsule, we added free RGDfK peptide (50 μM) into the cell culture medium 1 h 
before adding the RGDfK modified nanocapsule into HUVECs. After 1 h incubation, cells were 
washed and fixed as described in cellular uptake assay for the CLSM evaluation.  
 
3.2.8. Confocal laser scanning microscope (CLSM) observation of the fluorophores labeled 
nanocapsule 
To confirm that the nanocapsule was able to load two hydrophobic molecules simultaneously in a 
core-shell structure, we chose 6-coumarin and nile red, both of which are widely used 
hydrophobic fluorophores, to be encapsulated into the PLGA core and lipid bilayer, respectively. 
The two fluorophores were added at 0.05% concentration. Nanocapsule was prepared as 
described above with 6-coumarin loaded in the PLGA core and nile red embedded in between 
lipid bilayer. Then, the nanocapsule suspension was imaged with CLSM. As the diameter of the 
nanocapsule was close to the imaging limit of CLSM, we could only get the general view picture 
of the core-shell nanocapsule as shown in the manuscript.  
 
3.2.9 Co-culture assay 
To investigate the ability of nanocapsule for sequential antivasculature and anticancer activities, 
we conducted the co-culture assay to mimic the tumor microenvironment in vitro. MCF-7 cells 
were transfected with enhanced green fluorescent protein (eGFP) gene by Lipofectamine 2000® 
(Invitrogen) and sorted by FACS before used. For co-culture assay, HUVECs were cultured in the 
Lab-Tek® chamber at 20,000/well for 24 h. Then, transfected MCF-7 cells were added into each 
well at the density of 20,000/well for another 24 h, after which the cells were subject to different 
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treatment groups for the designated time points. At the end of each treatment, cells were fixed 
with 4% formalin and stained with propidium iodide (50 μg/ml) before CLSM imaging process. 
 
3.3 Results and discussion 
As shown in scheme 3-1, this cNC is a core-shell structure with PTX encapsulated in the core and 
CA4 embedded in the lipid bilayer. We chose poly(lactic-co-glycolic acid) (PLGA) as the core 
forming matrix as it is regarded as a biological friendly and degradable material widely used in 
biomedical application (83). The shell was composed of a lipid bilayer, which is also a 
biocompatible material used extensively in drug or gene delivery in the form of liposome or 
micelles. PTX is a potent chemotherapeutic agent for treatment of various of cancers (153). And 
CA4 is a vascular disrupting agent, aiming to cause rapid and selective shutdown of the 
established tumor vasculature, leading to the secondary tumor cell death when used alone (154). 
 




To control the size of the as-formed combinatorial nanocapsule (cNC) core, we employed a novel 
nanoprecipitation method reported recently (152). Under this method, the size of the core could 
be fine-turned from several tens nanometer to one hundred nanometer. This facilitates the 
manipulation of the core-shell cNC for wide applications. In addition, this lipid assisted 
nanoprecipitation is a one-step self-assembled progress so that less chemicals and/or synthetic 
chemistry steps are involved. This makes the nanocapsule preparation simple and robust for large 
scale production. Herein, we synthesized the core at about 100 nm so as to achieve satisfactory 
drug loading capacity and stability in aqueous environment for further processing (Figure 3-1a). 
Then, the self-assembled PTX loaded PLGA core with a hydrophilic PEG surface was further 
coated with a lipid bilayer as the shell with the CA4 loaded within the bilayer through the 
hydrophobic interaction. The size of the resultant cNC as determined by dynamic light scattering 
was found to be around 180 nm (Figure 3-1a and b) with a negative surface charge at -22 mV. 
     
b a 
Figure 3-1. Dynamic light scattering results of PLGA core and nanocapsule (a) and the particle 
size distribution of vasculature targeted nanocapsule (b). 
 
Scanning transmission electron microscopy (sTEM) image shows that the cNC is uniform and 
well-dispersed with a dark core and gray shell (as indicated by the dark and white arrow, 
respectively) (Figure 3-2a). To confirm the core-shell structure of cNC and its ability to load dual 
drug simultaneously, we used two hydrophobic fluorophores, 6-coumarin and nile red, to stain the 
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core and shell, respectively. The 6-cournarin which emits green fluorescence under excitation was 
used to be encapsulated into the PLGA core, and nile red emitting red fluorescence was to be 
loaded into the lipid bilayer. Under the excitation of laser scanning confocal microscope (CLSM), 
the two fluorophores could be detected under the same spots (Figure 3-2 b-d). This confirms the 
co-localization of the two fluorophores in the same cNC in a core-shell structure. 
 
We investigated the cytotoxicity of the PTX core alone to the MCF-7 breast cancer by MTS assay 
and the vascular disrupting ability of the CA4 in lipid formulation, respectively. It is shown that 
the PTX encapsulated core could induce the apoptosis of MCF-7 at around IC50=50 nM after 24 
hours incubation (Figure 3-3). For CA4 formulation, it could disrupt the β−tubulin of 
cytoskeleton at 2.5 µM in 24 h (Figure 3-4). 
 
a 
b c d 
6-coumarin channel Nile red channel Overlay 
53 
 
Figure 3-2 Scanning transmission electron microscopy (sTEM) image of vasculature targeted 
nanocapsule (a) and CLSM images of 6-coumarin fluorescence (b), nile red fluorescence (c), and 
their overlay image (d). Scale bar = 1μm. 
 
 
Figure 3-3 MCF-7 cellular viability assay induced by PTX containing PLGA core at different 
concentrations of equivalent PTX. Ctl: cell culture medium as control; Blk: blank nanocapsule 
without any drug. (n=6) 
 
To investigate the cellular affinity of RGD modified cNC and uptake efficiency, the primary cells, 
human umbilical vascular endothelial cells (HUVECs), were used to mimic the angiogenetic 
tumor vascular cells. Figure 3-5 and Figure 3-6 presents the HUVEC uptake of cNC at different 
time-points.  It can be seen that the uptake of RGD modified cNC (T-cNC) was prominent as 
early as 20 min (Figure 3-5a), and the uptake of cNC without RGD modification (NT-cNC) could 
only be obviously detected after 1 h incubation (Figure 3-6). At that time, the uptake of NT-cNC 
was just comparable with the T-cNC at 20 min incubation (Figure 3-6). This uptake process 
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suggested a time-dependent manner. And the cNC uptake became most prominent at 6 h after 




Blank lipid formulation 2.5 μM CA4 equivalent lipid formulation 
  
a b 
Figure 3-4 Immunofluorescence staining of β-tubulin of HUVEC after treated by blank lipid 






Figure 3-5 Cellular uptake of RGD targeted nanocapsules at 20 min (a) and 6 h incubation (b), 
respectively. Scale bar = 5 µm. 
 
Moreover, this targeting function of T-cNC could be reversed with prior addition of free RGD 
peptides at 50  µM (Figure 3-7). Thus, this cellular uptake assay evidenced the efficient uptake of 
T-cNC by HUVECs upon short-term exposure, which paves the road for sequential delivery of 
drugs for antivasculature and anticancer activities. 
 



























Figure 3-6 Time-dependent HUVEC uptake of RGD surface modified nanocapsule (a-d) and 
nanocapsule without RGD surface modification (e-h). Scale bar = 20 μm. 
 






Figure 3-7 Competition assay of HUVEC uptake of RGD surface modified nanocapsule without 
(a) and with (b) free RGD (50 μM) prior addition. The incubation time was 1 h for nanocapsule 
uptake. T-nanocapsule: RGD modified targeted nanocapsule. Scale bar = 20 μm. 
 
In vitro cumulative drug release assay (Figure 3-8) shows that the two drugs in cNC were 
released in a sequential manner. The delay of 50% of drug release was 36 h. There was a 
significant burst release of CA4 in the first 20 hours, and the PTX was released in a sustained 
manner which was consistent with other PTX nanoparticle formulations (155, 156). It was 
reported that the sustained drug release mechanism of the PLGA core was controlled by the 
density of lipid used for the construction of the PTX loaded core (152). Therefore, the PTX 
release manner from the PLGA core could be manipulated accordingly by varying the amount of 
lipid used during the self-assembled nanoprecipitation procress. 
36 h 
   
Figure 3-8 In vitro cumulative drug release profiles of nanocapsule for sustained release of 
combretastatin A4 and paclitaxel. Results are presented as mean ± s.e.m. (n=3). 
 
To prove the sequential drug delivery kinetics, we employed a previously reported endothelial 
cell - tumor cell co-culture assay (157) with minor modification. In this assay, the HUVECs were 
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co-cultured with green fluorescent protein (GFP) transfected MCF-7, followed by different 
treatments at designated time points. The results were evaluated by CLSM. 
 
As shown in Figure 3-9, after 42 h incubation, the CA4 lipid formulation resulted in substantial (~ 
90%) elimination of HUVECs, the endothelial cells and only approximately 30% elimination of 
the MCF-7 cancer cells. In comparison within the same incubation period, the PTX core showed 
compariable cytotoxicity to both endothelial and tumor cells (60% versus 50% elimination). 
However, cNCs showed substantial cytotoxicity to both endothelial and cancer cells even after 15 
h incubation. At the same time, the T-cNC was more cytotoxic than NT-cNC to both the 
HUVECs (P<0.0001) and cancer cells (P<0.001). In 42 h incubation time, the inhibition effect to 
HUVECs and the anticancer effect to cancer cells of both cNC were further improved; and 
meanwhile, marginal significant differential cytotoxicity T-cNC versus NT-cNC was found only 
on the endothelial cells (P < 0.01), but not on the cancer cells  This situation could be attributed 
to the efficient cellular uptake of the RGD modified nanocapsule in short incubation time, while 
in the longer incubation period, the cellular uptake of both targeted and non-targeted nanodelivery 
systems became similar, resulting in similar manner of HUVEC inhibition and cancer cell 
apoptosis. Overall, our targeted nanocapsule induced cell death in a sequential manner, i.e., 
causing the death of the vascular cells before the apoptosis of the MCF-7 cancer cells. The co-
culture assay confirmed the effectiveness of our RGD targeted cNC for sequential drug delivery 






Ctl (42h) Blk (42h) CA4 (42h) PTX (42h) 
             NT-cNC (15h) T-cNC (15h) NT-cNC (42h) T-cNC (42h) 
a 
 
Figure 3-9 Co-culture assay of endothelial and tumor cells with different treatment methods. (a) 
CLSM pictures present the effects of different group on endothelial cells (red) and MCF-7 tumor 
cells (yellow or green). (b) Quantitative result analysis of different treatment group on 
endothelium and tumor cells. Results are presented as mean ± s.e.m (n=3). Ctl: control group with 
cell culture medium; BLK: blank nanocapsule placebo; CA4: CA4 lipid formulation; PTX: PTX 




The reason underlining the sequential drug delivery design is that tumor hypoxia could be 
induced in the antiangiogenesis therapy, leading to the anti-apoptosis effect or drug resistance of 
tumor cells (158), what is worse, enhancing the possibility of metastasis of tumor cells (159), thus, 
the optimal sequential combinatorial treatment with antivasculature and anticancer drugs would 
obtain much more effective therapeutic results. It has been recently argued that antiangiogenetic 
therapy could sensitize the chemotherapeutic effect when used in combination treatment (160).  
And the success of large scale clinical trial also proved the effectiveness of the combination 
therapy for cancer treatment (161). 
 
3.4 Conclusion 
We have designed a novel robust combinatorial sequential drug delivery system for 
antivasculature and anticancer activities. This cNC remained the high cytotoxicity of anticancer 
drug encapsulated in the core, and could deliver drugs in a sustained manner to sequentially 
disrupt tumor vasculature and ablate tumor cells with the assistance of RGD targeting ligand. We 
envision that this vascular targeted sequential combinatorial approach may open another avenue 












Angiogenesis, the growth of new blood vessels from preexisting capillaries, is a fundamental 
process involved in the embryonic development and adult life. Physiological angiogenesis is 
vitally important in maintaining tissue functions and homeostasis (147, 162), whereas the 
angiogenetic feature in the solid tumor contributes to the tumor proliferation, migration and 
metastasis (163). During tumor cell development, the vasculatures provide the necessary oxygen 
and nutrients supporting the highly proliferating cancerous cells growth and invasion. Hence, 
angiogenesis targeted therapy was hypothesized as an essential therapeutic modality for the 
suppression of tumor growth and metastasis (164). In addition, the specific feature of tumor 
vasculature and its less likeliness of acquiring drug resistance owing to the genetic stability of 
endothelial cells makes the antiangiogenesis therapy promising in cancer treatment (165).  
Unfortunately, it was evidenced that tumor angiogenesis is a comprehensive result of multiple 
pathways, which are mutually associated and compensatory (149), this compensatory mechanism 
could limit the therapeutic effects from a single antiangiogenesis therapy. Thus, combining a 
conventional cytotoxic agent with an antiangiogenetic drug under optimal dosage could likely 
enhance the therapeutic effects, and reducing the potential side effects. Some recent studies on the 
therapeutic effect of the combined antiangiogenesis and conventional chemotherapy have shown 
the promising effects of this strategy in fighting against cancer (166, 167), especially in advanced 
metastatic cancer (161).  
 
Amongst the conventional chemotherapeutic agents, paclitaxel (PTX) has emerged as a wide 
spectrum of anticancer drug for treatment of various cancers, such as breast cancer, ovarian 
cancer, lung cancer, etc. PTX binds to the β-tubulin on cytoskeleton, and this disables the 
microtubule disassembling during mitosis in cell cycle, and finally leads to the apoptosis pathway 
in treated cancer cells. To disrupt the blood vessels which support tumor growth and spreading, 
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vascular disrupting agents such as combretastatin A4 (CA4), could take full use of the differences 
in the pathophysiology of tumor versus normal tissue blood vessels to selectively and efficiently 
shutdown the blood vessels in tumor, resulting in the deprivation of oxygen and nutrients of 
tumor cells (168). 
  
In this study, we formulated a novel targeted combination therapy consisting of PTX as an 
anticancer agent to induce cancer cell apoptosis, and CA4 as an antiangiogenetic agent to disrupt 
tumor vasculature. Since nanotechnology approaches have presented high potential in controlled 
delivery of drugs to numerous diseases, especially cancers (131), we encapsulated those two 
drugs into biodegradable nanoparticles (NP) for controlled delivery. Biodegradable polyesters 
such as poly(lactic acid) (PLA) or poly(lactic-co-glycolic acid) (PLGA) are extensively used in 
biomedical application due to biocompatibility, ability of loading various therapeutic compounds, 
and sustained drug released manner. Here, we chose PLGA as the building-up matrix to 
encapsulate drugs inside the nanoparticles. To enhance the tumor targeting selectivity and reduce 
the possible side effects arising from anticancer drugs, the NPs were surface modified with small 
peptides containing Arg-Gly-Asp (RGD) sequence. This RGD sequence was reported as a highly 
affinitive ligand to αvβ3 receptor overexpressed on many cancerous cells(83) and endothelial cells 
(151). Therefore, the objective of this study is to explore the delivery mechanism of this novel 
formulation, and investigate the combinatorial potency in treatment of metastatic cancer. 
 
4.2 Materials and methods 
4.2.1 Material 
PLGA (RG503H) was obtained from Boehringer Ingelheim (Germany). RGDfK cyclic peptide 
was purchased from AnaSpec (U.S.A.). CellTiter 96 AQueous Non-Radioactive Cell Proliferation 
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Assay was from Promega. Paclitaxel (microcrystalline white powder, purity >99 %) was obtained 
from 21 CEC company (Oaklands, UK). Combretastatin A4 was from (Toronto Research 
Chemicals, Canada). N-hydroxysuccinimide (NHS), N-(3-Dimethylaminopropyl)-N′-
ethylcarbodiimide hydrochloride (EDC), polyvinyl alcohol (PVA, M.W. 30,000-70,000), 
Dulbecco's Modified Eagle's Medium (DMEM) , and other necessary chemicals were of 
analytical grade, and were purchased from Sigma Chemical Co. (St. Louis, MO, U.S.A.). Human 
Umbilical Vascular Endothelial Cells (HUVEC) was generously provided from Prof. Ruowen Ge 
from the Department of Biological Sciences, National University of Singapore. Anti-β-tubulin 
primary monoclonal antibody was from Sigma Co. (MO, U.S.A.), other primary antibodies used 
in western blots were obtained from Cell Signaling Inc. All of the secondary antibodies involved 
in this study were purchased from Pierce Biotechnology. Deionized water (Millipore, Bedford, 
MA, U.S.A.) was used thorough the entire study. 
 
4.2.1 Preparation of drug loaded nanoparticles 
 
Nanoparticles containing either single drug or dual drugs were prepared using emulsion solvent 
evaporation method. In brief, 100mg PLGA and, if required, 10mg PTX and/or 20mg CA4, were 
dissolved in 5ml of dichloromethane to form organic phase. This organic phase was emulsified in 
40ml of 1% (w/v) aqueous PVA solution by probe sonication (50W out-put, 2 min, 2 s pulse) in 
an ice bath, followed by organic evaporation with magnetic stirring at 1000 rpm for 6 hours. The 
nanoparticles produced were collected and washed three times with deionized water by 
ultrafiltration (Millipore, Amicon®) at 4,000 rpm for 45 min. To make the nanoparticle 
fluorescent for uptake mechanism study, 6-coumarin, a widely hydrophobic fluorophore was 




To modified the nanoparticle surface with RGD peptide, the above as-prepared concentrated NPs 
were diluted with 0.1 M MES (pH 6.0), and then subject to ultrafiltration, and washed with 0.1 M 
MES twice, and finally dispersed in MES buffer. EDC and NHS were added into the nanoparticle 
solution at 0.1M and 0.25M, respectively, and this mixture was incubated for 2 hours, followed 
by washing three times with PBS (pH 7.4) and separated by ultrafiltration. Then, 1ml (2mg/ml) 
RGD peptide solution was introduced into the NPs solution under mild vortex. The reaction was 
allowed to proceed overnight, and the unconjugated peptides were washed off by ultrafiltration 
with PBS. 
 
4.2.2 Characterization of nanoparticles  
The mean diameter and polydispersity index were determined by dynamic light scattering (DLS) 
method using Zeta Sizer (Nano 90s, Malvern Instruments, England). The zeta potential of NPs 
was also characterized by Zeta Sizer. To determine the drug loading efficiency (LE) and 
encapsulating efficiency (EE), the nanoparticle solution was first lyophilized by freeze-drier, and 
then the pre-weighed nanoparticles were dissolved in acetonitrile, and incubated for 4 hours to 
completely release the encapsulated drugs from nanoparticles. Then, the solution was diluted 
using acetonitrile and water mixture at 50:50%. The drug content was analyzed by HPLC. The 
mobile phase was 50:50 acetonitrile:water at flow rate of 1mL/min and detection was made at 
wavelength of 227nm for PTX and 295 nm for CA4. 
 
The conjugation efficiency of RGD peptide onto the nanoparticle surface was determined 
according to the method reported previously (83). The morphology and microstructure of the NPs 
was visualized by scanning electron microscopy (SEM, JEOL, Japan). To prepare the sample for 
SEM imaging, the lyophilized NP powder was loosely scattered onto carbon conductor tape 
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supported with copper holder, and then the NPs were coated with Pt/Au before observing under 
SEM at 5kV voltage.   
 
4.2.3 Cellular uptake of NPs and their distribution in cells 
The cellular uptake of NPs by HUVEC was evaluated by confocal laser scanning microscope 
(CLSM). HUVECs were seeded in Lab-Tek® chambers (Nalgene, Nunc Inc., Denmark) at density 
of 2 x 104 per well, and allowed to attach for 24 hours. 6-coumarin labeled NPs were diluted with 
serum-free cell culture medium to 100μg/ml before adding to the cultured cells. At the designated 
time points (20min, 1, 4, and 8 h after incubation), the cells were washed three times with PBS, 
and fixed with 4% paraformaldehyde and Triton X-100 before staining with Texas Red® 
conjugated phalloidin, then the cells were washed with PBS, followed by adding DAPI to stain 
the cell nuclei. Optical images were obtained using Olympus Flowview FV1000 Confocal laser 
scanning microscope. A 60x objective aqueous lens was used equipping with 488nm argon, 
543nm HeNe and 405nm diode lasers. To investigate the cellular distribution of NPs in HUVEC, 
the cells were incubated with NPs (100μg/ml) for 1 h, before using endo/lysome tracker kit 
(Molecular Probes) according to manufacturer’s instruction.  
 
To further verify the internalization mechanism of NPs into cells through endocytosis pathway, 
we measured the cellular uptake of NPs in cold condition (4oC) versus normal cell culture 
condition (37oC). HUVECs were seeded on 24-well plate at density of 2x104 per well 24 h before 
experiment. 6-coumarin labeled NPs were incubated with cells for different times (20, 40, and 60 
min) at 4oC and 37oC, respectively. After incubation for the respective time points, cells were 
washed three times with PBS, and 0.2ml Trypan Blue aqueous solution (0.2mg/ml) was added for 
5 min to quench any non-internalized or non-specific absorbed NPs. After washing with PBS 
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twice, the cells were lysed with 0.2ml lysis buffer (0.1N NaOH/5% SDS) for 30 min. Cell 
extracts were measured for fluorescent signal with Multiwell plate reader (Tecan Group, Ltd, 
Switzerland) at excitation/emission of 488nm/530nm.  
 
4.2.4 Western blot to detect cellular apoptosis induced by PTX NPs 
Various concentrations of NPs containing PTX alone were added into cultured cells, and 
incubated for 48 h before western blot assay. For western blot assay, protein was extracted from 
treated cancer cells (B16F10) with lysis buffer (1% Triton X-100 with Proteinase inhibitor 
cocktail) on ice. The extracted proteins were separated with SDS-PAGE and transferred to PVDF 
membrane. The membrane was blocked by TBS buffer containing 5% skim milk for 1h. After 
washing with the washing buffer (TBS buffer with 0.1% Tween 20), the membrane was incubated 
with primary antibodies specific for cleaved caspases 3, caspase 7 and actin at room temperature 
for 2 h, respectively, and immunoblotted for 1 h with the corresponding secondary antibodies 
coupled with horseradish peroxidase. After extensive washing, bands were detected by 
SuperSignal West Pico Chemiluminescence Substrate (Pierce Biotechnology).  
 
4.2.5 Immnunofluorescence staining of tubulin 
To reveal the ability of NPs singly loaded with CA4 to disrupt endothelial microtubule 
cytoskeleton, cultured HUVECs were incubated with CA4 containing NPs (equivalent to 0.25μM 
drug) for 24 h. After the incubation, cells were fixed with acetone/methanol (1:1) mixture for 10 
min at -20oC, followed by sequential incubation with anti-β-tubulin primary antibody, and 
corresponding FITC coupled secondary antibody. Fluorescent images were taken using Nikon 




4.2.6 In vivo antitumor studies 
Cell culture. B16F10 mouse melanoma cells obtained from American Type Culture Collection 
(Rockville, MD) were cultured in Dulbecco's Modified Eagle's Medium (DMEM) supplemented 
with 10% fetal bovine serum, and 1% streptomycin and penicillin. The cells were maintained in a 
humidified atmosphere of 5% CO2 at 37oC. Cells grown in monolayer were sub-cultured by 0.05% 
trypsin/EDTA. The viability of cells was routinely monitored using Trypan Blue dye exclusion 
method. The cells were harvested during the logarithmic growth phase, and re-suspended in 
serum free medium before inoculated in animals.   
 
Subcutaneous tumor xenograft experiment. Animal procedures were performed according to the 
protocols approved by the university institutional animal care and use committee. The 
experiments were conducted in the Animal Housing Unit, National University of Singapore using 
6-8 weeks old C57BL6 male mice. For tumor development, B16F10 cells (0.5x106 in 0.1ml 
serum-free medium) were implanted subcutaneously in 6-8 weeks old C57BL6 male mice. The 
tumor was allowed to grow for 8 days when the tumor volume was about ~100 mm3 prior to the 
drug administration. Tumor bearing mice were assigned randomly into 6 groups of 5 mice each as 
follow: 1) RGD surface modified with two drug loaded NPs (T-Dual NP), 2 & 3) RGD surface 
modified with single drug loaded NPs (T-PTX NP or T-CA4 NP), 4) RGD surface modified 
blank NPs (BLK NP), 5) two drug loaded NPs without RGD surface modification (Dual NP), and 
6) PBS solution as control. All formulations were diluted with sterile PBS solution. Each tumor 
bearing mouse received PTX at 5mg/kg and CA4 at 20mg/kg by intravenous administration 
through the tail vein. The interval for each drug administration was 6 days for totally two times.  
Tumor diameters were recorded every 2 days with a digital caliper in 2 dimensions. Tumor 
volumes were calculated using the following formula: Tumor Volume=[Length x (Width)2]/2, 
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where length is the longest diameter, and width is the shortest diameter perpendicular to the 
length (169). 
 
4.2.7 Immunohistochemical staining 
Xenograft tissues were fixed in 4% paraformaldehyde for 2 days, and stored in 70% ethanol 
solution before experiment. Serial sections (5 μm thick) were deparaffinized in xylene and 
rehydrated through descending percentages of ethanol to water. Antigen retrival was done with 10 
mM citrate buffer (pH 6.1) for CD31 and Ki-67 antibodies. Endogenous peroxidase was blocked 
by 1% H2O2 methanol solution. For cell proliferation analysis, slides were incubated with Ki-67 
antibody (Abcam, 1:100) and CD31 antibody (Abcam, 1:100) was used for micro-vessel staining. 
Detection was done with diaminobenzidine chromogen, which results in brown color staining. 
The nuclei were counterstained with haematoxylin. Cellular apoptosis was carried out by reacting 
sliced tissues with terminal transferase dUTP nick end labeling (TUNEL) assay (Roche) 
according to the protocol from the manufacturer.  
 
4.3 Results 
4.3.1 Preparation and characterization of targeted nanoparticles  
Figure 4-1 presents the scheme of formulation process. Since both CA4 and PTX are hydrophobic 
compounds, it is easy to encapsulate both drugs simultaneously into PLGA matrix with a solvent-
evaporation method, followed by surface modification with EDC/NHS chemistry to conjugate 
RGD peptide onto the particle surface. The formulated nanoparticle is about 200nm as 
determined by dynamic light scattering method (Figure 4-1 insert). Table 4-1 summarizes the 
physical properties of NPs prepared in different formulations used in this study. It shows no 
significant particle size changes between the blank NPs and those drug loaded NPs. Nor did the 
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surface modification step significantly increase the NP size of the T-Dual NP in comparison to 
the Dual-NP. Although the drug loading and RGD modification slightly altered the particle size, 
the resultant NPs remained uniform in the size distribution as indicated by the polydispersity 
values (Table 4-1). All of the as-prepared NPs presented negative surface charge due to the 
carboxylic end groups on PLGA polyesters. The surface charge tended to become lower when 
drugs were loaded and RGD was conjugated to the particle surface. This is attributed to the 
inevitable drug absorption on the particle surface and/or the positive charge groups of RGD 
partially neutralizing the negative charge of NP. Fortunately, all of these minor changes did not 
adversely influent the physical properties of NPs, which makes this novel targeted combined drug 
delivery system robustly applicable for cancer therapy.  
                                                               
A B
Figure 4-1 RGDfK peptide surface modified poly(lactic-co-glycolic acid) (PLGA) nanoparticles 
encapsulated with paclitaxel and combretastatin A4. Schematic illustration of the targeted 
nanoparticle  dual-drug delivery system (A) and the scanning electron micrograph image of the 
resultant nanoparticles with smooth surface, clear boundary and uniform distribution (B) (Insert is 






Table 4-1 Characterization of nanoparticles in different formulations 
Nanoparticle Particle size (nm) Polydispersity Z-potential (mV) RGDfK (nmol/mg NP) 
T-Dual NP 244.1 ± 4.3 0.212 -11.4 ± 2.3 0.45 ± 0.08 
Dual NP 238.2 ± 4.9 0.093 -17.2 ± 3.2 N.A. 
T-PTX NP 240.0 ± 5.4 0.121 -12.5 ± 2.6 0.38 ± 0.12 
T-CA4 NP 234.2 ± 4.1 0.163 -10.8 ± 4.4 0.51 ± 0.06 
Blank NP 221.4 ± 1.1 0.082 -19.8 ± 2.1  N.A. 
Abbreviations:  T-Dual NP: RGD surface modified PTX and CA4 loaded nanoparticle; Dual NP; 
PTX and CA4 loaded nanoparticle without RGD surface modification; T-PTX NP: RGD surface 
modified PTX loaded nanoparticle; T-CA4 NP: RGD surface modified CA4 loaded nanoparticle; 
Blank NP: blank nanoparticle; N.A.: not available.  
 
4.3.2 Cellular uptake of nanoparticles  
We investigated the cellular uptake manner of NPs by HUVEC through confocal laser scanning 
microscope (CLSM). Fig. 4-2 (a-d) presents the time dependent uptake of NPs at 100μg/ml 
concentration. The uptake of nanoparticles by HUVEC was prominent as early as 20 minutes 
(Figure 4-2 a and e), and was the most significant after a 4-hour incubation (Figure 4-2 c). A 
longer incubation time (8 hours) could not further increase the nanoparticle uptake significantly 
(Figure 4-2 d and f). Thus, the resultant nanoparticles can be effectively taken up by HUVEC, 
and this provides a solid foundation to the high efficacy of the dual drug encapsulating 
nanoparticle for antivasculature and antitumor activities. 
 
To confirm the targeting ability of the RGD modified NPs was from the affinity of RGD to 
HUVEC, a higher concentration of free RGD peptides (50 μM) was added into the cell culture 
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medium before initiating the uptake experiment. The cellular uptake of RGD modified NPs was 











Figure 4-2. Cellular uptake of targeted nanoparticle and cytoplasm distribution. Confocal images 
showing uptake of nanoparticles by HUVEC at different time points: (a) 20min; (b) 1h; (c) 4 h; 
and (d) 8h. Red: actin filaments; Blue: cell nuclei; Green: targeted nanoparticles. (e) (with both 
bright and fluorescent illumination) and (f) (with fluorescent illumination only) show the 
distribution of nanoparticles in cytoplasm upon 1h incubation. Red: endosome/lysosome (black 
arrow); Green: nanoparticles (white arrow); Yellow/orange: overlay. The concentration of 





























Figure 4-3. Competition assay of cellular uptake of the targeted nanoparticles. Targeted or non-
targeted NPs (0.1mg/ml) were incubated with HUVECs for 1h. Then, the cells were washed 2 
times, followed by adding trypan blue to bleach any non-specific absorbed NPs on cell 
membrane. Cells were lysed in lysis buffer before measurement of fluorescence at 480/530 
ex/em. For the competition, 50 μM free RGDfK peptide was added into the medium before 
incubation with targeted nanoparticles. Data are presented as mean ± s.e.m (n=3) (*P<0.05). 
 
 
In the live-cell analysis, the co-localization of RGD modified NPs with endo/lysosome tracker 
staining suggested that the receptor mediated endocytosis underlined the cellular uptake 
mechanism (Fig. 4-2 g and h). This mechanism was further confirmed by incubation of NPs with 
HUVECs in cold (4oC) and normal (37oC) conditions, respectively. The uptake of NPs was 
reduced by nearly 50% at 4oC in the first 20min incubation. Whereas the NPs uptake became 
higher after longer incubation (60 min), the uptake of NPs in cold condition still remained much 



























Figure 4-4 Mechanism study of cellular uptake of nanoparticle. The cellular uptake of 
nanoparticles is a time and energy dependent process. At cold condition (4 degree), the uptake of 
nanoparticles was decreased by nearly 50% of that in normal condition (37 degree) at 20min, and 
even after 60 min incubation, the uptake in cold condition was still 68.5% of that in normal 
condition. Data are shown as mean ± s.e.m (n=3). (*, P<0.05; #, P<0.01) 
 
4.3.3 In vitro evaluation of efficacy of nanoparticles 
We investigated the potency of the formulated nanoparticles to induce apoptosis in cancer cells 
by PTX, and the ability of CA4 loaded nanoparticle to disrupt the HUVEC β-tubulin structure, 
respectively. To avoid the potential interference of two drugs in one formulation, we individually 
formulated each drug into nanoparticles. Fig. 4-5 demonstrates the western blot results of PTX 
loaded nanoparticle to malignant melanoma cancer cells (B16F10). It can be seen that 50 nM 
equivalent PTX is potent to induce the caspase 3 and 7 activation, indicating the undergoing 
apoptosis pathway upon the exposure of 50 nM PTX formulation, whilst a lower drug 
concentration (10 nM) could not function so efficiently. At 50 nM drug concentration, the PTX 
encapsulated nanoparticles dispersed in aqueous cell culture medium was as effective and 




 Figure 4-5. Western blot results indicated the potency of T-PTX NPs to induce caspase 3/7 
apoptosis pathway in B16F10 cancer cells at different drug concentration upon 24 h incubation. 
Control: culture medium; Blank NP: blank nanoparticle with RGDfK modification but no drug 




Fig. 4-6 shows the immufluorescent staining results of β-tubulin structure in HUVEC after 
incubation with the respective nanoparticulated CA4 at an equivalent concentration of 2.5μM 
(Fig 4-6 A) and the blank nanoparticles (Fig 4-6 B). Upon a 24-hour incubation, the blank 
nanoparticle treated HUVEC cells did not show any obvious β-tubulin disruption, whilst the 







Figure 4-6. Immunofluorescent staining of HUVEC illustrates β-tubulin disruption by 
combretastatin A4 (CA4) formulation. (A) presents the unchanged tubulin filament (white 
arrows) upon incubation with blank nanoparticle for 24 h; (B) shows the disrupted tubulin 
structure (white arrows) and changed cell morphology (white arrow head) after treatment by 
equivalent 2.5 M CA4 encapsulated NPs for 24 h.　  
 
4.3.4 Antitumor evaluation of different formulations 
 
We evaluated the biological activities of different formulated NPs for antiangiogenesis and 
anticancer activities in tumor bearing mice. Fig. 4-7 presents the results of the tumor volume 
changes as a function of treatment time with PTX and CA4 therapeutics either as single agents or 
in combination in nanoparticles. It can be seen that the tumor growth were significantly inhibited 
by the targeted dual drug loaded NPs from day 8 onward (P < 0.05), and from day 10 onward by 
the non targeted dual drug loaded nanoparticle (P < 0.05). In contrast, the 2 targeted single drug 
loaded nanoparticles at the given dose (5mg/kg PTX, 20 mg/kg CA4) showed discernable but 
statistically insignificant tumor growth inhibition throughout the whole study period. No mice 
died from the treatment in the entire experiment. However, it may be noted that the control 
groups and the respective treatment groups on the single drug loaded nanoparticle were 
terminated 2 days earlier than the treatment groups on the dual drug loaded nanoparticle, as their 
tumor sizes started to grow beyond the limit stipulated by the institutional animal care and use 
































Figure 4-7. Changes in tumor growth as a function of time in C57BL6 mice after intravenous 
treatment with PTX and CA4. The injection dose of PTX and CA4 was set at 5mg/kg and 
20mg/kg. The drugs were administrated on day 0 and 6, as indicated by arrows (* P<0.05, # 
P<0.05 vs control). 
 
4.3.5 Histological evaluation of different formulation treatment 
 
Tumor tissues with small and large vessels are delineated by CD 31 immunostaining (Fig. 4-8). It 
can be seen that untreated tumor (PBS) showed apparent lumen structure with large blood 
vessels, T-PTX NPs treated tumor resulted in discontinued vascular capillaries, and T-CA4 NPs 
presented a significant disruption of vasculatures in the tumor. Moreover, the most prominent 
disruption of tumor vasculature occurred in the T-Dual NPs treated group, accompanied by 
necrosis within tumor tissues (as indicated by black arrows). Tumor in the group treated with T-
Dual NPs showed the least proliferative activity, and other drug treated groups presented different 
level of proliferation reduction, as compared with the PBS treated group (Fig. 4-8). TUNEL 
examination of DNA fragmentation in tumor cell nuclei presented in Figure 4-8 revealed the 
potency of each formulation in inducing apoptosis to cancer cells. Tumor of the T-Dual NPs 
treated group showed the most significant TUNEL staining, with notable deformed cellular 
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morphology. Interestingly, tumor of the T-PTX NPs treated group showed less apoptotic effect 
than that of the T-CA4 NPs treated group. This may be attributed to the relative low PTX dosage 
as a single agent used in this study (5mg/kg).  
 
The change of body weight was recorded (Fig. 4-9). There was no significant body weight change 
in all of the treated and non-treated groups. The slight increase of body weight may be due to the 





Figure 4-8. Histology of tumor tissues with treatment of different formulations. CD 31 staining 
reveals the tumor vasculature; Ki 67 staining shows the extent of cell proliferation inhibition of 
different formulations; and TUNEL staining demonstrates the degree of apoptosis induced by 
various formulations. The paclitaxel and combretastatin A4 were given at dose of 5mg/kg and 






























Figure 4-9. Change in body weight during treatments 
 
4.4 Discussion 
Numerous studies have evidenced that the combination of antiangiogenic agents with 
conventional chemotherapeutic agents (170, 171) or radiotherapy (172) could have additive or 
synergistic effects against malignant cancers. In clinic, antiangiogenic agents as monotherapeutics 
have limited, if any, discernable efficacy, especially in the treatment of advanced malignant 
cancers.  And the conventional chemotherapy can result in the well-known drug resistance effect 
after long-term administration. This drug resistance sets a barrier for better treatment of cancer. In 
addition, due to the plasticity, tumors are likely to evade single targeted therapeutic method 
designated to control the proliferation and survival of tumor cells (150). Hence, formulation of 
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drugs with the respective antivasculature and anticancer activities could hold great potential for 
cancer therapy.  
 
In this study, PLGA was chosen as the matrix building-up material to encapsulate drugs into 
nanoparticles, followed by decorating the nanoparticle surface with targeting moiety. The PLGA 
or PLA have been extensively used in biomedical applications from drug delivery system to 
tissue engineering. Thus, this biocompatible and degradable material is more feasible to be 
translated to clinical practice than any other newly discovered biomaterials (131). Because of the 
hydrophobic feature of PLGA, it is of ease to encapsulate hydrophobic drugs, like PTX or CA4, 
into nanoparticulated form.  In addition, the availability of carboxyl end group of PLGA facilitate 
the further conjugation of targeting moieties for disease specific drug/gene delivery (173). 
 
As shown in Table 4-1, the resulted NPs presented negative surface charges that could enhance 
nanoparticle stability by decreasing the nonspecific absorption of protein onto the NPs during 
circulation. The RGDfK peptide conjugated onto the nanoparticle surface is supposed not only to 
target some specific cancer cells which overexpress integrin receptors on cell membrane, but also 
to orient the NPs to the proliferating tumor vascular cells where integrin receptors are specifically 
overexpressed (151). In this sense, nanoparticulated drugs could be more selectively accumulated 
at the tumor site. 
 
Efficient cellular uptake of NPs plays a vital role in the delivery of drugs to cancer cells so as to 
initiate the apoptotic pathways. Figure 4-2 shows that the RGD modified NPs were taken up by 
HUVECs as early as 20 min. And this uptake trend could be, to some extent, inhibited by prior 
addition of free RGDfK peptides (Fig 4-3). This highly efficient cellular uptake may explain the 
efficient onset of cytotoxicity of T-PTX NPs to cancer cells (Fig. 4-5). Since PLGA based drug 
delivery system usually presents a sustained-release manner for encapsulated drugs (145),  it 
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takes some time (usually 48 hours) for the sequestered anticancer drugs to show significant 
cytotoxic effect. However, in our system, the encapsulated PTX presented effective cytotoxic 
effect in 24 hours at equivalent drug concentration of 50 nM, which is comparable to the PTX 
directly dissolved in DMSO (Fig. 4-5).  
 
The CA4 loaded targeted NPs also presented good potency in disruption of β-tubulin of HUVECs 
in 24 hours (Fig. 4-6). Upon release from the NPs, CA4 can bind to tubulin at or close to the 
colchicines-binding site (174), and result in rapid re-organization of the actin cytoskeleton, 
mediated by disruption of the tubulin cytoskeleton. This process was reported to be associated 
with the Rho/Rho-kinase, as well as stress-activated protein kinase 2 (SAPK2) dependent 
pathways (175). Unlike other antiangiogenetic agents such as bevacizumab (Avastin), a 
recombinant monoclonal antibody targeted to VEGF that leads to transient “normalization” of the 
tumor vasculature (176), CA4 is a vascular disrupting agent that induces tumor vasculature 
permeability, leading to further shutdown of tumor blood flow, and finally resulting in increased 
tumor hemorrhage and necrosis (154).  
 
Even though PTX was used at relatively small dose (5mg/kg), the combination of such low dose 
of PTX with CA4 (20mg/kg) in targeted NPs achieved substantial therapeutic effect in the 
B16F10 tumor bearing mice (Fig. 4-7) than the single agent loaded NPs. Besides, the tumor in the 
group treated with the targeted dual-drug loaded NPs demonstrated substantial antivasculature 
and anticancer therapy as evidenced by the immunohisochemical (IHC) staining results (Fig. 4-8).  
Figure 4-8 shows that the T-Dual NPs were able to induce widespread tumor vasculature 
disruption (CD 31 staining), extensive cytotoxicity (TUNEL), and strong proliferation inhibition 




In cancer therapy, the commonly employed strategy is to use high dose of drugs for patients so as 
to achieve maximum treatment efficacy. Nevertheless, the side-effects associated with such high 
dose treatment are concerned for the benefit of patients. Thus, individualized low dose anticancer 
drug administration should be a plausible method for cancer treatment, but this low dose strategy 
may bear the risk of not achieving effective therapeutic effects, especially in those malignant 
cancers. It has been recently reported that low dose of PTX could be deliver to tumor site to 
achieve encouraging therapeutic effect by nanotubes, because of the long-circulation time and 
high tumor cell uptake of that nanostructured material (177). With our developed delivery system, 
although there existed the therapeutic effect by T-PTX NPs as single agent administrated at 
5mg/kg, the average tumor growth was still 11.5-fold of the initial tumor size, whilst that in the 
T-Dual NPs group was much lower, just 5.4-fold. Meanwhile, the equivalent concentration of 
CA4 in T-CA4 NPs group presented even higher tumor growth (13.3 fold). This significant 
therapeutic effect of T-Dual NPs may be due to the fact that CA4 was released to the tumor 
microenvironment upon T-Dual NPs anchoring to either tumor cell or tumor vasculatures within 
tumor microenvironment, leading to the disruption of tumor vasculature; and the simultaneously 
released PTX efficiently induced apoptosis of cancer cells. Since CA4, a vascular disrupting 
agent resulted in the higher vascular permeation, the resultant leaky tumor vasculature might, in 
turn, facilitate the penetration of NPs into the tumor microenvironment to accumulate drug at 
high concentration within the tumor. This enabled enhanced cytotoxic effect of PTX to cancer 
cells. Furthermore, with more cancer cells died, the growth factors secreted by cancer cells could 
also be dramatically reduced. The available low concentration of growth factors would not be 
able to support the subsequent neovasculature growth. Then, our targeted nanoparticulated 
combination therapy could exert both antivasculature and anticancer activities.  
 
Up to date, various antiangiogenesis therapies have been proposed for cancer treatment, ranging 
from regulation of transcription factor expression (178) to combining antiangiogenetic agent with 
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anticancer drugs (179) or treatment with combination of drugs in addition to radiotherapy (180). 
Each strategy possesses its own distinctive feature for effective treatment of cancer. 
Unfortunately, most of the strategies involved the complex drug administration routes and 
schedules, which may make the combination therapy difficult to follow in practice. From 
practical point of view, it will be more convenient, if the combination therapy method could be 
realized in a simple way. Our targeted nanoparticulated combination therapy aiming at 
neovasculature and malignant cancer cells could simultaneously, to some extent, simplify the 
drug administration route, as well as the schedule. More importantly, the appropriate combination 
of drugs could significantly enhance the therapeutic efficacy as an organic whole. Therefore, this 
novel targeted nanoparticulated combination therapy may offer a formidable armament in 
fighting against malignant cancers. 
 
4.5 Conclusion 
In this study, we prepared a novel tumor vasculature targeted nanoparticle loading with 
chemotherapeutic drug (PTX) and vascular disrupting agent (CA4) for simultaneous anticancer 
and antiangiogenesis therapy. The cellular uptake of nanoparticle was efficient. The nanoparticle 
loaded with PTX could efficiently induce apoptosis in cancer cells, and disrupted the cytoskeleton 
when loaded with CA4, respectively. Xenograft tumor model presented the effective therapeutic 
effects by targeted dual-drug loaded nanoparticle treatment, and histological tests also confirmed 
the mechanism of efficacy by inducing cancer cell apoptosis and tumor endothelial cell death. 






Sequential drug delivery by nanocapsule for targeted disruption of 
























Metastasis is regarded as the primary cause for most malignant cancer death (19). During the 
metastatic process, primary tumor cells rely much on the tumor neovasculature for proliferation, 
invasion, extravasation, and eventual arrestment and growth at the new site (181). Thus, 
neovasculature in tumor microenvironment was attributed for the pathogenesis of primary tumor 
growth and metastasis (149). As early as 1971, Folkman had proposed the concept that blocking 
angiogenesis would lead to the tumor dormancy, which is nowadays well-known as 
antiangiogenesis therapy (40). Over the past years, thousands of results have been reported on 
antiangiogenesis for cancer therapy, and some potent compounds have achieved successful 
clinical trial outcomes (161, 165).  However, it was evidenced that tumor angiogenesis is a 
comprehensive result of multiple pathways, which are mutually associated and compensatory, 
this compensatory mechanism could limit the therapeutic effects from the single antiangiogenesis 
therapy (149). In addition, the single agent antiangiogenesis therapy may result in tumor hypoxia 
which upregulates the genes that adversely impair the therapeutic effects (182), and may also lead 
to the drug resistance of tumor cells (158). Hence, the combination of a conventional cytotoxic 
agent with an antiangiogenetic drug under optimal dosage with rational design could likely 
enhance the therapeutic effects, and reduce the potential side effects in cancer therapy (149).  
 
Up to now, there have been numerous reports on the combinatorial treatment of cancer with drugs 
to inhibit different pathways for either additive or synergistic effects (149, 166, 178, 183). 
Nevertheless, those combinatorial methods required multiple administrations of therapeutic 
agents at different schedules. This makes the combinatorial treatment inconvenient in practice. In 
addition, there is a paradox in the antiangiogenesis therapy, which usually requires long-term 
high dose administration of antiangiogenic agents, and cytotoxic chemotherapy on a shorter 
regimen (157, 184). To address these concerns, Sengupta et al. proposed that delivery of 
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antiangiogenesis and anticancer drugs in an integrated sequential release manner would, to some 
extent, circumvent these obstacles for more effective cancer therapy (157). Their research group 
fabricated a nanoscale pegylated-phospholipid block-copolymer envelope coating a polylactic 
glycolic (PLGA) nuclear nanoparticle. The designed nanocell enabled a temporal release of two 
drugs: the outer envelope first released an antiangiogenesis agent, causing a vascular shutdown; 
the inner nanoparticle, which was trapped inside the tumor, then released a chemotherapy agent. 
The prepared nanocell resulted in improved therapeutic index with reduced toxicity. However, 
their nanocell system involved complicated preparation process which may be a hurdle for future 
scale-up production; and the therapeutic efficacy of the anticancer agent was also compromised 
after amide bond conjugation to the polymer. The relative large size of their nanocell (in the 
range of 180 – 200 nm) may not be ideal for targeting to the tumor site through the enhanced 
permeability and retention (EPR) effect.   
In this study, we designed a novel nanocapsule through much simpler steps for sequential 
delivery of combretastatin A4 (CA4) and paclitaxel (PTX) for antivasculature and anticancer 
activities. We chose appropriate molecular weight of Methoxyl poly(ethylene glycol)-poly(lactic 
acid) (mPEG-PLA) as the building-up matrix (83). The PTX was conjugated with ending group 
of PLA with cleavable ester bond, and CA4 was encapsulated in the core when the mPEG-PLA 
self-assembled in aqueous environment. Our nanocapsule was highly uniform and much smaller 
in size in the range of 70 nm. Both in vitro and in vivo experiments evidenced the significant 
therapeutic effects to malignant tumors by the nanocapsule.  
5.2 Materials and methods 
5.2.1Material 
 D, L-lactide was generously supplied by PURAC biomaterials (Netherland). Poly(ethylene glycol) 
(mPEG) (M.W. 2,000) with one end methoxyl group and stannous octate were supplied by Sigma 
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Chemical Co. (St. Louis, MO, U.S.A.). Copolymer mPEG-PLA was synthesized by ring opening 
polymerization of D, L-Lactide initiated by mPEG with stannous octate as catalysist (0.5% w/w) in 
our laboratory. Paclitaxel was obtained from 21 CEC company (Oaklands, UK). Combretastatin 
A4 was purchased from Toronto Research Chemicals, Canada. All other necessary chemicals 
were of analytical grade, and were purchased from Sigma Chemical Co. (St. Louis, MO, U.S.A.).  
 
5.2.2 Cell lines and animals.  
Human Umbilical Vascular Endothelial Cells (HUVEC) was generously provided from Dr. 
Ruowen Ge from the Department of Biological Sciences, National University of Singapore. 
B16F10 mouse melanoma cells, Lewis Lung Carcinoma (LLC) cells were obtained from 
American Type Culture Collection (Rockville, MD). Animal procedures were performed 
according to the protocols approved by the university institutional animal care and use committee. 
All the experiments were conducted in the Animal Housing Unit, National University of 
Singapore using 6-8 weeks old C57BL6 male mice. 
 
5.3.3 Drug conjugation and nanocapsule preparation method 
We functionalized the copolymer with carboxyl acid ending group by adding 10 molar ratio of 
succinic anhydride to the as-synthesized copolymer with DMAP as catalyst, and this reaction was 
carried out for 2 days at 60 oC under argon atmosphere. Then, the resultant raw product was 
washed with 0.1% HCl and brine solution twice. The organic phase was separated and dried on 
anhydrous magnesium sulfate, followed by filtration and vacuum drying. Then the carboxyl acid 
functionalized copolymer was conjugated with PTX at the C-2’-OH position by the method 
reported previously (185). The nanocapsule was prepared by nanoprecipitation method: 100 mg 
copolymer with conjugated PTX and 20 mg CA4 were dissolved in 10 ml acetonitrile. Then, the 
mixture was dropped into 20 ml distilled water under vigorous magnetic stirring. The 
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nanocapsule was collected after stirring for 6 h by ultrafiltration (Millipore, Amicon®) at 4,000 
rpm for 30 min, followed by PBS washing three times. To facilitate the cellular uptake analysis, 
intracellular distribution study and biodistribution tracking, nanocapsule was labeled with 6-
coumarin fluorescent dye by dissolving the 6-coumarin (0.05% w/v) in organic phase during the 
nanocapsule preparation.  
 
5.2.4 Characterization of nanocapsule  
The mean diameter and polydispersity index were determined by dynamic light scattering (DLS) 
method using Zeta Sizer (Nano 90s, Malvern Instruments, England). The drug loading efficiency 
(LE) and encapsulating efficiency (EE) were determined by HPLC method. For the HPLC 
analysis, the mobile phase was 50:50 acetonitrile:water at flow rate of 1mL/min and detection 
was made at wavelength of 227nm for PTX and 295 nm for CA4, respectively. 
 
To study the morphology of nanocapsule, transmission electron microscopy (TEM) images were 
taken on the day of preparation and 10 days after preparation. To study in vitro kinetic release of 
nanocapsule, 1 ml concentrated nanocapsule solution was sealed in dialysis membrane, which 
was submerged in 10ml PBS (pH 7.4) with orbital shaking at 100 rpm at 37oC. At designated 
time points, 200 μl of PBS solution was withdrawn and refilled with same amount of fresh PBS. 
All the aliquots were kept at -80 oC until HPLC analysis by the method mentioned above.  
 
5.2.5 Uptake of nanocapsule by HUVECs and intracellular distribution in cells 
The cellular uptake of nanocapsule by HUVEC was evaluated by confocal laser scanning 
microscopy (CLSM). HUVECs were seeded in Lab-Tek® chambers (Nalgene, Nunc Inc., 
Denmark) at density of 2 x 104 per well, and allowed to attach for 24 hours. 6-coumarin labeled 
nanocapsules were incubated with HUVEC at 100μg/ml.  At the designated time points (20min, 1, 
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2, 4, and 6 h after incubation), the cells were washed three times with PBS, and fixed with 4% 
paraformaldehyde for FACS analysis. For confocal microscopy, cells were further treated with 
Triton X-100 before staining with Texas Red® conjugated phalloidin, and then the cells were 
washed with PBS, followed by adding DAPI to stain the cell nuclei. Optical images were 
obtained using Olympus Flowview FV1000. To investigate the cellular distribution of 
nanocapsule in HUVEC, the cells were incubated with nanocapsule (100μg/ml) for 1 h, before 
using endo/lysome tracker kit (Molecular Probes) according to manufacturer’s instruction. To 
further confirm the internalization mechanism of nanocapsule into cells through endocytosis 
pathway, we measured the cellular uptake of NPs in cold condition (4oC) versus normal cell 
culture condition (37oC). 
 
5.2.6 Annexin V/propidium iodide apoptosis staining assay 
To study the kinetic sustained release of PTX from PTX-copolymer conjugate, we used two-color 
flow cytometric analysis with Alexa Fluor® 488 labeled annexin V and propidium iodide staining 
assay. In this assay, CA4 was not included to exclude any possible interference on results. 
B16F10 Cells were cultured and incubated with PTX containing nanocapsule for different times 
(24, 48, 72 and 96 h) at an equivalent PTX concentration of 1 μg/ml. At the end of incubation, 
cells were stained with reagents from Vybrant® Apoptosis Assay Kit (Molecular Probes) 
following manufacturer’s instruction and analyzed using Dako Cytomation Cyan LX flow 
cytometer. 
 
5.2.7 Scratch assay  
To demonstrate the potential of CA4 in inhibiting the HUVECs growth after loaded in the 
nanocapsule, we conducted the scratch assay with only CA4 encapsulated nanocapsule at 
equivalent CA4 concentration of 2.5 μM. HUVECs were cultured in gelatin-coated chamber slide 
90 
 
at density of 2 x 104 cells/well. CA4 loaded nanocapsule was diluted with cell culture medium 
and incubated with HUVECs for 24 h, after which scratches were applied with 20 μl pipette tips. 
Slides were washed with HBSS buffer for 3 times before incubated in cell culture medium for 
another 24 h. Then, cells were fixed and imaged.  
 
5.2.8 Tube formation assay 
To demonstrate the effective vasculature disruption ability of CA4 loaded nanocapsule, we used 
the 3-D matrigel tube formation assay at an equivalent CA4 concentration of 2.5 μM. HUVECs 
(P<5) were cultured on Matrigel thin layer with 40ng/ml VEGF in 24 well plate at 3 x 104 
cells/well for 24 h. Then, the CA4 loaded nanocapsule was diluted with cell culture medium 
before incubated with cells for another 24 h. Cells were imaged with Nikon Eclipse TE200 
inverted microscope equipped with cooled CCD camera.  
 
5.2.9 Body distribution and toxicity studies of nanocapsule 
We evaluated the body distribution and tissue retention of the nanocapsule using a fluorescent 
marker, 6-coumarin. The high loading and fluorescent quantum yield characters enabled the 
selectively track the distribution of nanocapsule in vivo (186). Mice were xenografted with LLC 
tumor cells (0.5 x 106) subcutaneously in 6-8 weeks old C57BL6 male mice. After 8 days when 
the average tumor size reached 200 mm3, 100 μl 10mg/ml fluorescence labeled nanocapsule was 
injected from the tail vein. At defined time points, mice were sacrificed, and spleen, liver, kidney, 
heart, lung and tumor were collected, and blood was drawn through cardiac puncture. To exclude 
tissue toxicity, histological analysis (H&E staining) of liver, heart and kidney was conducted; and 




5.2.10 In vivo Matrigel plug assay 
The Matrigel assay was conducted to assess the antiangiogenesis potency of dual drug loaded 
nanocapsule in vivo. Experiment was conducted as previously reported with minor modification 
(84). Mice were subcutaneously injected on the flank with 500 μl growth factor-reduced Matrigel 
(BD bissciences) and PBS mixture with 400 ng/ml of human recombinant bFGF (Millipore). 
Nanocapsule with different types of drug loading was intravenously injected on day 1, 3 and 5 at 
equivalent PTX 1mg/kg and CA4 5 mg/kg, respectively. On the seventh day, mice were i.v. 
injected 20 μg fluorescein-labeled G. Simplicifolia lectin that selectively binds to mouse 
endothelial cells (Vector Labs). The Matrigel plugs were removed, imaged and viewed whole-
mount by confocal microscopy or homogenized, and the fluorescent singles were quantified by 
multiwell plate reader (Tecan Group, Ltd, Switzerland) at excitation/emission of 488nm/530nm. 
 
5.2.11 In vivo primary tumor experiment 
LLC cells (0.5 x 105) were implanted subcutaneously into 6-8 weeks old C57BL6 male mice. The 
drug administration started when the average tumor size reached ~100 mm3. The drug-loaded 
nanocapsule solution in PBS was administered through tail vein every other day at drug dose of 
PTX 5mg/kg and CA4 20mg/kg, respectively. Tumor bearing mice were assigned randomly into 
5 groups of 5 mice each as follow: 1) PTX and CA4 dual loaded nanocapsule (Dual NC); 2) 
single agent PTX or CA4 loaded nanocapsule (PTX NC or CA4 NC); 3) blank nanocapsule 
without any agent (BLK NC); 4) PBS buffer solution (PBS). Tumor size and animal weight were 
monitored every 2 days. The tumor volume was measured with digital caliper in two dimensions 




5.2.12 Liver metastasis prevention experiment 
To examine the effect of dual drug loaded nanocapsule for prevention of liver metastasis 
development, liver metastasis was developed by spleen injection of tumor cells (B16F10, 1 x 
106/50 μl PBS). Drug was administered every other day. After 20 days, the experiment was 
terminated. Mice were sacrificed and autopsied. Livers were removed for histological H&E and 
IHC evaluation.   
 
5.2.13 Immunohistochemistry evaluation of angiogenesis, proliferation and apoptosis in 
tumor 
For cell proliferation analysis, serial sections (5 μm thick) were incubated with Ki-67 antibody 
(Abcam, 1:100), CD31 antibody (Abcam, 1:100) was used for micro-vessel staining, and VEGF 
antibody (Abcam 1:200) for growth factor. Detection was done with diaminobenzidine 
chromogen. The nuclei were counterstained with haematoxylin. Cellular apoptosis was carried 
out by reacting sliced tissues with terminal transferase dUTP nick end labeling (TUNEL) assay 
(Roche) according to the protocol from the manufacturer. To detect the metastases of B16F10, a 
melanoma cell in liver, liver sections were stained with an anti-mouse melanoma primary 




5.3.1 Physicochemical characterization of nanocapsule 
PTX incorporation efficiency to copolymer was around 82% as determined by HPLC method. 
The nanoprecipitation method was widely used to encapsulate hydrophobic drug into 
amphiphiphlic copolymer which self-assembled into micellar structure in aqueous environment 
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(155). For nanocapsule preparation, the drug loading efficiency of CA4 was about 52% as also 
determined by HPLC method. Figure 5-1a illustrates the preparation of nanocapsule. The average 
size of the nanocapsule is around 68.3±1.4 nm with a narrow particle size distribution of 0.156 
(Fig. 5-1b).  Figure 5-1c presents the TEM images of day-0 and day-10 nanocapsule, respectively. 
The size remained almost unchanged after 10 days settlement with well-dispersed particle 
distribution.  
 
In vitro drug release of nanocapsule showed that there was distinctive drug release profile 
between PTX and CA4 in the nanocapsule (Fig. 5-1d). The CA4 release profile showed a bi-
phase drug release manner in the micelle delivery system where the loaded drug was released 
with burst release followed by a sustained release manner for a longer period. However, the 
conjugated PTX presented a sustained release pattern with slight early peak burst on the first day 
of incubation  
 
Figure 5-1. Synthesis and physicochemical characterization of the nanocapsule. A, Synthetic 
scheme of nanocapsule. B, A typical dynamic light scattering (DLS) analysis of nanocapsule 
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suspended in aqueous medium. C, TEM pictures of nanocapsule suspend in water. The spherical 
and well-dispersed uniform structures of nanocapsule are shown at day 0 and day 10 of 
preparation. Scale bar = 100 nm. D, In vitro kinetic release of paclitaxel conjugate and 
combretastatin A4 in PBS (pH 7.4) over 14 days. The results are presented as mean ± s.d.  
5.3.2 Nanocapsule uptake by endothelial cells through endocytosis 
The uptake of nanocapsule took place after as early as 20 min incubation with HUVECs. After 2 
h incubation, the uptake came to the maximum level, and longer incubation time (4 and 6 h) 
could result in aggregates in the cytoplasm (Fig.5-2a). In the FACS analysis, 2 h incubation was 
sufficient to saturate the uptake of nanocapsule into HUVECs, and there was no much difference 
in fluorescent signals between 2, 6 and 24 h incubation (Fig. 5-2b). The co-localization of 
endo/lysome tracker with nanocapsule suggested the endocytosis as the possible uptake 
mechanism (Fig. 5-2a). This was further confirmed by incubating HUVECs under cold (4 oC) and 
normal (37 oC) conditions, respectively (Fig. 5-2c). The uptake of nanocapsule by HUVECs in 
cold condition was only 50% of that in normal condition at the 20 min incubation. After 1 h 
incubation, the uptake of nanocapsule was still 30% less in the cold condition as compared with 
that in normal condition.  
 
5.3.3 Sustained release of conjugated paclitaxel from nanocapsule induced apoptosis in 
cancer cells 
It can be seen from Figure 5-3 that the cell apoptosis became significant after 48 h incubation. 
After 72 h and 96 h incubation, the late apoptosis/necrosis condition presented along with the 
early apoptosis. This condition is consistent with the in vitro conjugated PTX release profile 
where conjugated PTX was sparsely released out of nanocapsule in 24 h incubation, but longer 
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Figure 5-2. HUVEC uptake of nanocapsule. A, Upper two rows: confocal laser scanning 
microscopy (CLSM) images of HUVEC uptake of 6-coumarin labeled nanocapsule after 20 min, 
1, 2 and 6 h incubation period. The representative magnified pictures at 20min (M) and 6 h (M) 
are also presented. Scale bar = 20 μm (normal pictures); 10 μm (magnified pictures). Red: actin 
filament; Green: nanocapsule; Blue: nuclei. Bottom row: Live HUVEC images of 1 h incubation 
of HUVEC with 6-coumarin labeled nanocapsule. Endo/lysosome is presented in red; and 
nanocapsule is shown in green. Overlay between micelles and endo/lysosomes is presented in 
orange/yellow color. B, FACS analysis of HUVEC uptake of 6-coumarin labeled nanocapsule. 
Graphs of 0 min, 20 min, 2 h and 24 h are shown. Incubation at 4 h and 6 h followed the similar 
pattern as the one in 2 h (data not shown). C, HUVEC uptake of nanocapsule at cold (4oC) and 
normal (37oC) conditions at different time points. 
97 
 
5.3.4 The potency of CA4 loaded nanocapsule in inhibiting HUVEC proliferation and 
initiating vascular disruption effect in vitro  
In the scratch assay, the proliferation inhibition of CA4 loaded nanocapsule to HUVEC was in a 
dose and time-dependent manner. 1 μM was effective to block the growth of wounded HUVEC 
monolayer in 24 h incubation. Longer incubation time (48 h) showed more prominent 
proliferation inhibition results (Fig. 5-4 a). In the tube formation assay, 0.1 μM equivalent CA4 
concentration could substantially disrupt the tube formation in 24 h incubation (Fig. 5-4 b).  
 
 
Figure 5-3. FACS analysis of Annexin V/propidium iodide apoptosis induced by sustained 
released PTX conjugate in nanocapsule. A, the FACS graphs of apoptosis induced by sustained 
released PTX conjugated in nanocapsule (equivalent drug concentration = 1μg/ml). B, Statistical 
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Figure 5-4. CA4 loaded nanocapsule in HUVEC migration inhibition and tube formation 
disruption ability. A, CA4 loaded nanocapsule inhibits the migration of HUVEC in scratch assay 
in the dose and time-dependent manners. B, CA4 loaded nanocapsule results in the disruption of 
as-formed vascular tubes at different equivalent drug concentrations in 24 h incubation time. Both 
controls are cell culture media with corresponding blank nanocapsules. 
 
5.3.5 Biodistribution, tumor accumulation and tissue toxicity studies of nanocapsule 
Results (Fig. 5-5a) showed the values of fluorescence signals in tissues in three individual mice at 
8 h after given a single dose of nanocapsule intravenously. It can be seen that high concentration 
of fluorescent signal appeared in liver, tumor and kidney tissues. We also evaluated the 
distribution of nanocapsule in liver, spleen, kidney and tumor tissues at three different time points 
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(4, 8 and 24h) (Fig. 5-5b). Similarly, liver and tumor presented the highest concentration of 
fluorescence labeled nanocapsule at all time points. Interestingly, the concentration of 
nanocapsule in liver and kidney demonstrated a descending trend, whereas the tumor mass 
showed an ascending accumulation of nanocapsule over time. In serum, the fluorescence labeled 
nanocapsule could still be detectable after 72 h (Fig. 5-5c). At 24 h, when the signal in serum 
dropped substantially, the tumor mass, in contrast, showed the highest signal value.  
 
Histological analysis (H&E) revealed that there were no abnormalities detected in the liver, 




Figure 5-5 Biodistribution study of nanocapsule. A, Fluorescent signal of tissue extracts after 8 h 
circulation time. Mice (n=3) were intravenously injected with single dose of 6-coumarin labeled 
nanocapsule (10mg/ml). The graphs present three different mice in this treatment group, 
autofluorescence from tissue was omitted by subtracting the fluorescent signal values from 
untreated mice. B, Distribution of nanocapsule with 6-coumarin in high vasculature organ at 4 h, 
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8 h and 24 h after single dose i.v. injection of nanocapsule. C, Fluorescent signal from mouse 
serum at different time points after single dose i.v. injection of labeled nanocapsule. (n=3) 
 
5.3.6 Antiangiogenesis effect of nanocapsule in the Matrigel® plug model.  
Mice treated with dual drug loaded nanocapsule presented significant neovasculature inhibition, 
whilst single PTX conjugated nanocapsule presented slight antiangiogenesis effect (Fig. 5-7a). 
The dual drug loaded nanocapsule presented more than 90% angiogenesis inhibition, CA4 loaded 
nanocapsule showed 76.6% inhibition effect, PTX conjugated nanocapsule demonstrated 45% 
inhibition when compared to the PBS treated mice group (Fig. 5-7b). These findings indicate that 
dual drug loaded nanocapsule produced substantially higher antiangiogenesis effect.  
 
5.3.7 Antivasculature and primary tumor growth inhibition effects of nanocapsule 
Dramatic tumor growth was observed in the PBS treated group during the treatment period, 
whilst all of the drug treated groups presented tumor growth inhibition to different extents (Fig. 5-
8a). At day 10 of treatment, the inhibition effect of the dual drug load nanocapsule was 76.6%, 
single CA4 loaded nanocapsule was 63.5% and single PTX conjugate loaded nanocapsule was 
23.2%. Mice in the blank nanocapsule treated group demonstrated similar tumor growth as those 
in the PBS control mice (Fig. 5-8a). Figure 5-8b shows the representative picture of the dissected 
tumor tissues in different treatment groups. No apparent side effects, including body weight loss 
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Figure 5-6. H&E staining of mouse tissues dissected from mice intravenously injected with 
10mg/ml (nanocapsule concentration) nanocapsule for toxicity evaluation. Images are taken at 







































P < 0.01 
 
Figure 5-7. Vascular disruption of different formulated nanocapsules in the mouse Matrigel plug 
assay model. A, Pictures of dissected Matrigel plugs from different treatment groups. Mice were 
s.c. implanted with Matrigel plugs, followed by i.v. injected with different formulations of 
nanocapsules on day 1, 3, and 5. On day 7, mice were i.v. injected G. simplicifolia lectin before 
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plugs were removed from animal bodies. B, Quantification evaluation of fluorescence tagged 




Figure 5-8 The therapeutic effect of nanocapsule to inhibit primary tumor proliferation and 
angiogenesis without toxicity. A, Therapeutic effects of different formulated nanocapsules on 
established lewis lung carcinoma (LLC) tumor: mice (n=5) were i.v. injected with equivalent 
PTX of 5 mg/kg and CA4 20 mg/kg every other day. B, Representative pictures of LLC tumor 
removed from mice at the end of the experiment on day 12 of treatment. C, Change of body 
weight during experiment. PBS: PBS buffer treated control group; CA4 NC: single CA4 loaded 
nanocapsule; PTX NC: single PTX conjugate loaded nanocapsule; BLK NC: blank nanocapsule; 




In histology, tumor section in PBS treated group had both small and large vessels with the lumen 
structure as indicated by CD31 staining. However, in the single CA4 loaded nanocapsule, there 
were just some tiny or disrupted blood vessels, whilst the PTX nanocapsule treated group 
remained large mature vessels. In contrast, the dual drug loaded nanocapsule resulted in more 
undeveloped and/or disrupted tumor vessels (Fig. 5-9a and b). In addition, the dual drug loaded 
nanocapsule showed much less cancer cell proliferation evidenced by Ki67 staining amongst all 
of the treated groups and untreated groups (BLK NC and PBS groups) (Fig. 5-9a and c). The 
apoptosis detected by TUNEL staining suggested that the dual drug loaded nanocapsule also 
induced the most cellular apoptosis compared to any other groups (Fig. 5-9a and d)  
 
As vascular endothelial growth factor (VEGF) is a major pro-angiogenesis factor in tumor 
microenvironment, we also tested the VEGF expression level in tumor tissue after different 
treatments. It can be seen from Figure 5-10 that the VEGF expression level was significantly 
inhibited in the dual drug loaded nanocapsule treated group along with the disconnection of the 
tumor cell junction (arrow) and change of cell morphology. Other treated and control groups all 
presented much less therapeutic effect on VEGF inhibition. 
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Figure 5-9. Histology of tumor tissues with treatment of different formulations. A, Tumor section 
with CD 31 staining reveals the tumor vasculature ; Ki 67 staining shows the extent of cell 
proliferation inhibition of different formulations ; and TUNEL staining demonstrates the degree 
of apoptosis induced by various formulations. And statistical results of immunohistochemical 
staining on different treatment tumors. B, the stained (CD31) vasculature size distribution in each 
treatment group. C, Ki67 results indicate tumor cell proliferation in different treatment groups. D, 
TUNEL results show the apoptosis of tumor cells after different treatment methods. All counting 
results were conducted in 6 different fields under 40X magnification. *P<0.05 v.s. PBS. All 
images are 20X magnification. PBS: PBS buffer treated control group; CA4 NC: single CA4 
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Figure 5-10 VEGF expression level with different formulated nanocapsule treatment. All images 
are 20X magnification. PBS: PBS buffer treated control group; CA4 NC: single CA4 loaded 
nanocapsule; PTX NC: single PTX conjugate loaded nanocapsule; Dual NC: dual drug loaded 
nanocapsule. 



























Figure 5-11. Therapeutic and preventive effects of different formulated nanocapsules on liver 
metastasis from B16F10 injected spleen. A, histology of liver tissues from different formulated 
nanocapsules with H&E (upper panel) and IHC (lower panel) stainings (with an anti-mouse 
melanoma antibody, 1:100, Abcam) B, Survival curve of assigned nanocapsule treated mice 
(n=6). Treatment started at day 2 after tumor cell spleen injection. P=0.0217 vs. PBS. PBS: PBS 
buffer treated control group; CA4 NC: single CA4 loaded nanocapsule; PTX NC: single PTX 
conjugate loaded nanocapsule; Dual NC: dual drug loaded nanocapsule. T: tumor; L: Liver. 
 
5.3. 8 Liver metastasis prevention of nanocapsule.  
The respective treatment was administered every other day for 18 days. The liver tissues were 
then harvested from the test animals on day 20 for the H&E and immunohistochemical (IHC) 
staining of the liver tissue sections (Fig. 5-11a). The liver tissue from the PBS treated group 
presented enlarged liver with serious cirrhosis. The staining results showed extensive tumor 
invasion and serious liver cell apoptosis (H&E). In contrast, the result from the dual drug loaded 
sequential delivery nanocapsule treated group showed no significant tumor cell metastasis and 
liver cell death, but just sporadic tumor cells in the liver without significant tumor lesions (IHC 
staining results). The single drug loaded nanocapsule (either CA4 NC or PTX NC at the same 
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dosage) could not inhibit the formation of tumor lesion in the liver. Figure 5-11b shows the 
survival curve of the respective treatment groups.  
 
5.4 Discussion 
Angiogenesis, the growth of new blood vessels from preexisting capillaries, is a crucial process 
for tumor proliferation, migration and metastasis formation (163). Tumor microendothelial cells 
have become the secondary therapeutic target for effective cancer treatment (187).  
 
In this study, we developed a novel sequential drug delivery nanocapsule loaded with dual drugs 
for the respective antivasculature and anticancer activities. Vasculature targeting agent, CA4, was 
chosen to induce selective regression of atypical tumor blood neovasculature (188), and 
conventional chemotherapeutic drug, PTX, was conjugated with mPEG-PLA for sustained 
controlled release after accumulation at the tumor site.  
 
The nanoprecipitation method employed in this study produced uniform and small particle size 
even after loading two drugs. In addition, the as-prepared nanocapsule was stable during the 
experiment period. The in vitro drug release study confirmed the fast release of CA4, followed by 
sustained controlled release of conjugated PTX, which is controlled by the slow hydrolysis of 
ester bond between PTX and PLA polymer similar to the  mechanism of other delivery system 
reported in our previous study (83). In culture, the reason underlining the efficiency cellular 
uptake may be due to the small and uniform particle size and its protective PEG shell, allowing 
the nanocapsule well dispersed in cell culture medium with less protein absorption (177). This 
could be translational to similar advantage in in vivo. The uptake mechanism was proved to be 
energy dependent endocytosis. The cultured Annexin V/propidium iodide apoptosis assay showed 
that the sustained but continuous released PTX remained high cytotoxic activity for tumor cell 
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apoptosis induction in a time dependent manner. The effective HUVEC growth inhibition study 
in scratch assay and tube formation disruption assay evidenced the high potency of the 
nanocapsule encapsulating CA4 for antivasculature activity in vitro. 
 
Biodistribution studies followed the similar pharmacokinetic pattern as other nanoparticulated 
drug delivery systems (189). The accumulation of nanocapsule at tumor site may attribute to the 
enhanced permeability and retention effect (EPR) arising from the inherent leaky tumor 
vasculature (128, 190).   
 
The artificial angiogenesis in Matrigel® plug implanted mice showed that the dual drug loaded 
sequential delivery nanocapsule was the most effective with over 90% inhibition compared to the 
PBS control group. It had been reported that low concentration of PTX has the antiangiogenesis 
property (191), so the sustained released PTX in the nanocapsule could potentially impart the 
antiangiogenesis effect.  Meanwhile, CA4 can bind to tubulin at or close to the colchicines-
binding site, and result in rapid re-organization of the actin cytoskeleton, mediated by disruption 
of the tubulin cytoskeleton (174). Thus, the antiangiogenesis effect from the two drugs may 
contribute to the significant antiangiogenesis inhibition in comparison with single agent loaded 
nanocapsules.  
 
In LLC tumor bearing mice, the dual drug loaded nanocapsule indeed presented the most 
significant tumor growth retarding effect at equivalent drug dose of PTX 5mg/kg and CA4 
20mg/kg. The relatively low but effective drug dose used in our study could be due to the long 
circulation time and efficient of cellular uptake of the materials of several tens of nanometers 
(177). In addition to the IHC results, the data from this tumor xenograft model suggest that the 
dual drug loaded sequential delivery nanocapsule is potent for antivasculature and anticancer 
activities. The exact therapeutic mechanism of this novel nanocapsule is not clear, but may be due 
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to the condition that rapid occlusion of tumor vasculature by CA4 with subsequent missive 
hypoxia and tumor necrosis may augment and/or sensitize the chemotherapeutic efficacy of PTX 
similar to the hypothesis proposed by Kerbel, et al (160). Besides, taking the dual drug loaded 
nanocapsule as an organic whole, the disrupted tumor vasculature by prior released CA4 may 
play a critical role to sequester PTX conjugate in the tumor environment under the sequential 
delivery nanocapsule similar to the proposed mechanism of nanocell reported previously (157).  
 
Tumor cell metastasizing to liver is very common in various tumor types associated with poor 
prognosis and less effective therapy (192). When we treated mice with this nanocapsule in the 
liver metastasis model, the dual drug loaded sequential delivery nanocapsule resulted in 100% 
mice survival in the 20 day experiment, with less tumor metastasis as uncovered by histological 
staining. Thus, our nanocapsule has emerged as a good example for sequential combinatorial 
treatment of liver metastasis. 
 
There are several limitations in the nanocell delivery system developed by Sengupta, et al (157).  
To overcome these limitations, we introduced novel approaches to fabricate our nanocapsule. For 
preparation, the dual drug delivery system of our nanocapsule employed a straightforward and 
robust one-step nanoprecipitation method with much less toxic chemicals involved. More 
importantly, our nanocapsule was about 70 nm in size with narrow size distribution, whilst the 
nanocell presented as large as nearly 200nm. Even though they did not mention the size 
distribution of their nanocells, their sizes appeared to be highly variable as indicated in their 
figure.  It was reported that smaller particle size would help the penetration of nanoparticle into 
the deep microenvironment of tumor mass through the leaky tumor vasculature under the EPR 
effects. It would be much more effective if  the size is less than 100 nm (108). As larger particle 
size may enhance the risk of arousing immune response, that may compromise the therapeutic 
effect of drug loaded nanoparticle (193). It has been reported that the molecular weight of 
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polymer is a critical factor in determining the release and efficacy of polymer conjugated drugs 
(83, 194). The large molecular weight of PLGA (61kDa) used by Sengupta et al. may delay the 
hydrolysis of the polymer-drug conjugate, thus leading to compromised anticancer drug efficacy. 
The molecular weight of PLA used for our nanoparticle was optimized at 2 KDa. It could lead to 
efficient hydrolysis of the conjugate in the cytoplasm. In addition, the conjugation of PLGA to 
the 3’-NH2 group of doxorubicin via amide bond in their study did not release doxorubicin in the 
original drug form but as the Doxo-3’-lactamide prodrug (195), leading to compromised 
therapeutic effect when used alone. In contrast, in our nanocapsule, the 2’-OH of paclitaxel was 
conjugated to the carboxyl end of PLA via ester bond that could be easily cleaved by hydrolysis 
upon cellular uptake (177).  By choosing a suitable polymer and optimizing the molecular weight 
of the build-up polyester and the synthetic route for the polymer-drug conjugation,  effective drug 
loading and sequential release of drugs were achieved with our novel nanocapsule.  
 
5.5 Conclusion 
We have fabricated a novel combinatorial drug delivery nanocapsule with sequential delivery 
feature for effective antivasculature and anticancer activities in vitro and in vivo. The findings in 
this study could encourage further investigation of other combinatorial treatments administered in 
the same or similar delivery systems for effective malignant cancer therapy. In addition, this 
novel nanocapsule delivery system could be employed as a template for other applications, such 
as by adding iron oxide nanoparticle in the core of the system for the simultaneous non-invasive 




Chapter 6  






In this thesis, we investigated combinatorial drug delivery by nanoparticulated particle for 
simultaneous antiangiogenesis and anticancer therapy. With the rapid advancing of 
nanotechnology, nanoparticulated drug delivery systems play important roles in biomedical 
applications, including cancer therapy. Nanoparticles loaded with therapeutic agents could extend 
the circulation time of drug in human body, accumulate anticancer drug at specific tumor sites, 
and alleviate the potential side-effects of drugs. Therefore, many investigations have focused on 
the novel drug delivery systems from synthesizing basic materials components to delivery system 
fabrication methods.  
 
Nevertheless, few efforts have been paid on the therapeutic effects of drug delivery systems on 
the malignant metastatic cancers. In the metastatic progress of tumor cells, angiogenesis in tumor 
microenvironment is a key player for tumor malignance and widespreading in the entire body. 
Thus, the antiangiogenesis therapy was popularly explored, ever since this concept was proposed 
by Folkman in 1971 (40). Along with the better understanding of biological process of  
angiogenesis and corresponding discovery and development of antiangiogenic agents, numerous 
lines of evidences have proved that antiangiogenic agents as monotherapeutics have limited, if 
any, discernable efficacy, especially in the treatment of advanced malignant cancers.  On the 
other hand, the conventional chemotherapy can result in the well-known drug resistance effect 
after long-term administration. This drug resistance sets a barrier for better treatment of cancer. In 
addition, due to the plasticity, tumors are likely to evade single targeted therapeutic method 
designated to control the proliferation and survival of tumor cells. Although the developed drug 
delivery systems could, to some extent, alleviated the drug resistance effects of many anticancer 
drugs and deliver drug in high pay-load to tumor sites, as well as diminishing the side-effects, 
more effective combination therapy drug delivery systems with simultaneous antiangiogenesis 
and anticancer activities are urgently desired.  
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Herein, we hypothesize that drug delivery system under controllable drug release features with 
combined antiangiogenesis and anticancer agents could more efficiently and effectively suppress 
the growth of malignant tumor masses, decrease the angiogenesis progress, and prevent the 
metastasis of such tumors in cancer therapy.  
 
In chapter 2 of this thesis, a small peptides containing Arg-Gly-Asp (RGD) sequence was 
selected as the targeting moiety. This RGD sequence was reported as a highly affinitive ligand to 
αvβ3 and αvβ5 receptors overexpressed on many cancerous cells (83) and highly proliferating 
tumor endothelial cells (151). In this chapter, we first investigated the potency of RGD surface 
modified nanoparticle with tethering PEG for delivery of conjugated doxorubicin to different 
types of malignant metastatic cells. Experiments had demonstrated that the synthesized NPs in 
this study were able to effectively target conjugated doxorubicin to malignant integrin expression 
cancer cells, and showed profound apoptotic induction effect to those cells. Although the drug 
efficacy to cancer cells was compromised after conjugation with PLGA, the resultant sustained 
release behavior and the property of selective uptake of the NPs by cancer cells could still make 
Doxo-PLGA-PEG-cRGD NPs a good candidate for anticancer therapy.  
 
In chapter 3, we explored the endothelial cell targeting ability of RGD surface tagged 
nanocapsule with temporal antiangiogenesis and anticancer drug release feature by using a robust 
self-assembly nanoprecipitation method. The combinatorial nanocapsule preserved the high 
cytotoxic effect of the anticancer drug encapsulated in the core, and could deliver the drugs in a 
controlled sustained manner to disrupt tumor vasculature and ablate tumor cells sequentially with 
the assistance of RGD targeting ligand. Results from chapter 2 and chapter 3 evidenced that these  
targeted nanoparticulated delivery systems hold the ability for effective anticancer or 
simultaneous antiangiogenesis and anticancer therapy.  
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In chapter 4, we encapsulated two drugs, PTX and CA4 for the respective anticancer and 
antiangiogenesis effects, into a RGD targeted nanoparticle, the matrix of which was composed of 
biodegradable PLGA polyester. The cellular uptake of the prepared nanoparticle was efficient. 
The nanoparticle loaded with PTX could efficiently induce apoptosis in cancer cells, and disrupt 
the cytoskeleton when loaded with CA4, respectively. Xenograft tumor model confirmed the 
effective therapeutic effects of targeted dual-drug loaded nanoparticle, and histological tests also 
established the mechanism of efficacy by inducing cancer cell apoptosis and tumor endothelial 
cell death. Therefore, we envision that this robust targeted nanoparticle with combined therapy 
for antiangiogenesis and anticancer activities may show a formidable candidate for cancer 
therapy.  
 
In chapter 5, we further explored our concept and applied with a more advanced and a well-
defined micellar delivery system, in which the polyester was conjugated to PTX to form a core 
for the controlled and sustained anticancer drug delivery, The polyester-PTX conjugate was 
further used to physically encapsulate CA4 for the antiangiogenesis function. Interestingly, we 
found that without RGD targeting function, micelles with appropriate particle size and PEG 
surface tethering could be uptaken by endothelial cells efficiently, and induce cytoskeleton 
disruption effectively upon fast CA4 releasing. The drug release profile could also be adjusted 
accordingly by conjugating the drug to the polyester with different molecular weights, and by 
altering the encapsulation parameters. The biodistribution experiments demonstrated the long 
circulation of nanocapsule in body fluid and the preferential accumulation of nanocapsule in 
tumor. Both in vivo artificial pro-angiogenesis and tumor xenograft assays demonstrated the 
promising therapeutic effect of the nanocapsule on tumor vasculature disruption, tumor cell 
proliferation inhibition and tumor cell apoptosis induction. The intrasplenic liver metastasis 
experiment also confirmed the liver metastatic prevention capacity of this novel nanocapsule. In 
summary, the findings indicated that this novel dual drug loaded micelle with sequential drug 
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delivery capacity is a promising candidate in combinatorial therapy in fighting against cancer, and 
may open an avenue for cancer therapy and diagnosis. 
In summary, this thesis demonstrated the in vitro and/or in vivo efficacy of several prototypes of 
nanoparticulated delivery systems for combinatorial temporal drug delivery for antiangiogenesis 
and anticancer therapy. The fabrication of these systems is robust and simple and can be easily 
modified for the other combinatorial temporal drug delivery. Last but not least, we hope that our 
study could, to some degree, contribute to the advance of cancer research for better healthcare.  
 
6.2 Future Direction 
For the future study of this project, there are still some important issues to be addressed: firstly, 
the different pharmaceutical formulations developed in this study need to be further optimized to 
enhance the drug loading efficiency and encapsulation efficiency and provide high nanoparticle 
stability; secondly, other promising tumor vasculature and/or cancerous cell surface receptor 
targeting ligands such as antibodies or small molecules other than the RGD sequence containing 
peptide widely used in this study could be utilized for the active targeting purpose; thirdly, some 
imaging contrast agents could be co-encapsulated in the appropriate nanoparticle formulation for 
simultaneous bioimaging to monitor the therapeutic function arising from the drugs; fourthly, 
other tumor animal models could be used to further evaluate the therapeutic efficacy of these 
delivery systems in cancer treatment. In addition, a broader range of tumor types, such as prostate 
cancer, breast cancer, brain cancer, may be adopted to establish the versatile therapeutic effects of 
the developed nanoparticles. The application of these systems for gene therapy, such as siRNA 
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